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Abstract 
Prostate cancer is the second most common cancer in men worldwide. Of almost 1.3 million 
newly diagnosed men per year, up to 80% will have localized disease with a characteristically 
prolonged natural history. Risk stratification and treatment decision-making for these men is 
currently based on the combination of standard clinical and histopathological predictors, such 
as the Gleason score, prostate specific antigen (PSA) level and clinical tumor stage at 
diagnosis. However, these standard predictors are not sufficient to capture the heterogeneity 
in prognosis for men with localized prostate cancer. As a consequence, these men are often 
overtreated and may suffer from treatment-related side effects. In this thesis we aimed to 
improve prognostication for men with localized prostate cancer through validation of existing 
risk stratification tools based on standard clinical and histopathological factors, and through 
validation of existing, and identification of novel, prognostic markers. 
In Study I, we evaluated if the nested case-control study design is appropriate for estimating 
relative and absolute risks of dying from prostate cancer in the presence of competing risks. 
We used a case-control study (ProMort I) nested in the National Prostate Cancer Register of 
Sweden (NPCR). We found that the relative risks of dying from prostate cancer estimated in 
ProMort I were comparable to the relative risks estimated in the NPCR. The relative risks of 
dying from other causes estimated in ProMort I were biased, which led to biased estimates of 
the absolute risks of dying from prostate cancer. The bias in both the relative and absolute 
risks was reduced by augmenting competing-risks cases, and especially by augmenting both 
the competing-risks cases and the controls. Our results indicate that, without the additional 
extensions to the design, the nested-case control studies are not suitable for the development 
of models predicting death from prostate cancer in the presence of competing risks. 
In Study II, we systematically compared the prognostic performance of the most commonly 
used pretreatment risk stratification tools in predicting death from prostate cancer using data 
from the Prostate Cancer data Base of Sweden. The Memorial Sloan Kettering Cancer Center 
nomogram, Cancer of the Prostate Risk Assessment score and Cambridge Prognostic Groups 
discriminated death from prostate cancer better than the D’Amico and D’Amico-derived risk 
grouping systems. The order of performance remained after stratifying by primary treatment 
and year of diagnosis. Using these tools could improve clinical decision-making. 
In Study III, we evaluated if a virtual microscopy system which we developed for central re-
review in ProMort I and Study IV can be used interchangeably with standard light 
microscopy for the histopathological evaluation of prostate cancer. We found good 
repeatability (i.e., intra-observer agreement) and reproducibility (i.e., inter-observer 
agreement) for several key prostate cancer histopathological features (i.e., core length, tumor 
length, primary and secondary Gleason pattern, the Gleason score and the Gleason Grade 
Groups (GGs)) both within and between light and virtual microscopy. The repeatability 
and/or reproducibility for some of the rare, or less commonly reported, features and for the 
percentage of Gleason pattern 4 was poor. The repeatability and/or reproducibility for these 
features should be improved before they are used in prognostic models. For all evaluated 
features, the agreement was similar within and between light and virtual microscopy 
indicating that light microscopy and our internally developed virtual microscopy system can 
be used interchangeably for the histopathological evaluation of prostate cancer.  
In Study IV, we evaluated if the International Society of Urological Pathology (ISUP) 
revisions of the Gleason grading systems have improved prostate cancer prognostication. We 
used a nested case-control study (ProMort II) to compare the prognostic performance of the 
pre-2005 Gleason score and the ISUP 2014 Gleason score. In our study, the ISUP 2014 
Gleason score discriminated death from prostate cancer better than the pre-2005 Gleason 
score. Our results also indicate that this improvement may be due to classifying all cribriform 
patterns, rather than poorly formed glands, as Gleason pattern 4. We then evaluated if other 
histopathological features can further improve the prediction of death from prostate cancer. 
The number of cores with ≥50% cancer involvement, comedonecrosis and high-grade 
prostatic intraepithelial neoplasia (HGPIN) predicted death from prostate cancer 
independently of the GGs. Only comedonecrosis and HGPIN remained independent 
predictors when added to the model with all the standard predictors (the GGs, age, PSA and 
clinical tumor stage at diagnosis). Adding these features had minimal impact on the model 
discrimination. 
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Figure 1.1. Prostate cancer incidence and mortality in Sweden, 1970-2018. Source: The Swedish Cancer
Registry and the Cause of Death registry, the National Board of Health and Welfare, Sweden
1 Introduction 
1.1 Prostate cancer 
1.1.1 Incidence  
In 2018, prostate cancer was the second most common cancer in men worldwide with an 
estimated 1.3 million newly diagnosed cases (1). It was the most frequently diagnosed cancer 
in 105 countries of the world, most notably in developed regions such as the North America, 
Northern and Western Europe and Australia (1). In Sweden, where prostate cancer was the 
most common cancer in 2018, almost 11,000 men were diagnosed with prostate cancer (2, 3). 
Prostate cancer incidence has been marked by a slow increase until the early 1990s (and 
somewhat later in the Nordic countries), followed by a more dramatic increase corresponding 
to the introduction and adoption of prostate specific antigen (PSA) testing (4, 5) and, finally, 
a slow decrease in subsequent years (Figure 1.1). Given the low specificity and the high false-
positive rate of the PSA test, routine PSA screening led to unnecessary prostate biopsies, 
overdiagnosis of indolent cancers and, ultimately, to overtreatment (6). For this reason, the 
US Preventive Services Task Force (USPSTF) has made several changes to the screening 
recommendations over time (7-9) and the trends in PSA testing, and, possibly, the trends in 
prostate cancer incidence seem to follow the timing of the changes in the USPSTF 
recommendations (10-12). After completely discouraging the use of PSA screening tests in 
2012, in 2018 the USPSTF recommended PSA testing for men aged 55 to 69 based on 
individual assessment (9). 
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1.1.2 Mortality 
With an estimated 359,000 men dying from prostate cancer in 2018, prostate cancer was the 
fifth most common cause of cancer-related death in the world (1). In Sweden, 2,500 men died 
from prostate cancer making it the leading cause of cancer-related death in men in 2018 (3, 
13). 
Unlike the incidence, prostate cancer mortality has been mostly stable or decreasing over 
time (Figure 1.1), likely due to the improved treatment and increased detection of early stage 
disease as a result of PSA screening (5, 14, 15). While PSA screening has undoubtedly led to 
an increased detection of prostate cancer, especially of localized prostate cancer, the effect on 
prostate cancer-specific mortality is still a subject of debate (16). Conflicting evidence from 
two major trials, the prostate arm of the Prostate, Lung, Colorectal and Ovarian Cancer 
Screening Trial (PLCO) (17) and the European Randomised Study of Screening for Prostate 
Cancer (ERSPC) (18), has been a major driver of this debate (5). The PLCO trial reported no 
survival benefit due to PSA screening after 13 and 17 years of follow-up (17, 19). On the 
other hand, the ERSPC reported an overall 21% reduction in cancer-specific mortality in the 
PSA screened arm at 13 years of follow-up (18) and the results were further confirmed by an 
updated analysis at 19 years of follow-up (20). A direct comparison of the results is, however, 
difficult due to the differences in implementation and settings of the two trials. Furthermore, 
76% of the men in the control arm of the PLCO trial had at least one PSA test during the 
study period (21), while in the ERSPC trial there was almost no PSA contamination (20). 
When these differences were taken into account, analyses indicated compatible results with a 
25-31% and 27-32% reduction in prostate cancer mortality due to PSA screening in the 
ERSPC and PLCO intervention groups, respectively (22, 23). While the ERSCP trial showed 
a reduction in cancer-specific mortality overall, published results from the Goteborg (24, 25), 
Spanish (26), Finish (27, 28) and Rotterdam (29, 30) sections of the trial are not uniform. 
Three sections report no reduction in prostate cancer mortality due to PSA screening (26-28) 
while the remaining sections report a reduction in prostate cancer mortality (24, 25, 29, 30). 
In addition, results from a large randomized clinical trial conducted in the United Kingdom 
(31) also report no reduction in prostate cancer mortality due to the PSA screening.  
1.1.3 Overdiagnosis 
Screening for prostate cancer aims at identifying high-risk, localized prostate cancer that can 
be successfully treated. Successful treatment would, in turn, prevent the morbidity and 
mortality associated with advanced or metastatic prostate cancer. However, PSA screen-
detected cancers are mostly asymptomatic cancers that would not cause symptoms and, 
otherwise, be detected nor contribute to death. This is known as overdiagnosis.  
As a part of the informed update of the USPSTF 2012 recommendations (5) the extent of 
overdiagnosis was evaluated in all the major PSA screening trials (17-20, 24-31). 
Overdiagnosis was estimated to range from 16.4% (17, 19) to 47.9% (29, 30) of all prostate 
cancers, and from 20.7% (17, 19) to 58.9% (29, 30) of all screening detected prostate cancers. 
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Overdiagnosis estimates are highly influenced by differences in study populations and 
screening practices as well as by the methods used for quantifying overdiagnosis. This is 
summarized in a review by Leob et al. where the estimates of overdiagnosis ranged from 
1.7% to 67% across the range of different methods and underlying populations with differing 
screening protocols (32). 
1.1.4 Overtreatment 
Treatment options for prostate cancer include upfront radical treatment with curative intent 
(i.e., radical prostatectomy or radiation therapy), deferred treatment with curative intent (i.e., 
active surveillance), deferred treatment without curative intent (i.e., watchful waiting) and 
upfront androgen deprivation therapy without curative intent. Treatment decision-making is 
primarily driven by prostate cancer prognosis and life expectancy (33-37). However, in the 
absence of clear guidelines and strong scientific evidence, treatment of localized cancer is 
heavily influenced by patients’ and clinicians’ preferences and beliefs (38).  
While men with high-risk prostate cancer are typically offered upfront radical treatment (38, 
39), treatment decision is more complex for men with low- or intermediate-risk disease. As, 
currently, no marker can separate indolent cancers from fast-developing cancers requiring 
treatment, overdiagnosed men are often overtreated, which, in turn, may lead to unnecessary 
treatment related side effects such as persistent urinary, sexual and bowel morbidities (5, 40-
43). Even with the increased utilization of active surveillance, over 50% of men with low- or 
intermediate-risk disease are still treated radically (38, 39, 44, 45). The potential harms of 
diagnosis and treatment should be balanced by improved life expectancy in men with low- 
and intermediate-risk disease. While upfront radical treatment may reduce the risk of 
metastatic disease, the long-term effect on prostate cancer mortality is not clear (46-48). 
1.2 Risk stratification 
Treatment decision-making in prostate cancer is mostly driven by prostate cancer prognosis 
and life expectancy (33-37, 49). Men with prostate cancer are typically classified into risk 
groups based on their clinicopathological features, such as PSA level, clinical tumor stage 
(cT) and Gleason score. In 1998, D’Amico combined these features and grouped men with 
localized prostate cancer into low-, intermediate- and high-risk groups (49). The D’Amico’s 
risk stratification system quickly became the main standard in clinical practice and the basis 
for risk stratification in all major prostate cancer guidelines (i.e., the European Association of 
Urology (EAU) (37, 50), the National Institute for Health and Care Excellence (NICE) (33), 
the Genito-Urinary Radiation Oncologists of Canada (GUROC) (34), the American 
Urological Association (AUA) (35), and the National Comprehensive Cancer Network 
(NCCN) (36)). Incorporation of more granular clinicopathological information (e.g., 
separating Gleason score 3+4 from 4+3) or introduction of additional clinicopathological 
parameters (e.g., measures of tumor extent in the diagnostic biopsies) led to further sub-
classification of these risk groups into very low- and low-risk group, favorable and 
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unfavorable intermediate-risk group and high- and very high-risk group (36, 51-55). The 
D’Amico and D’Amico-based risk grouping systems used in all major prostate cancer 
guidelines are presented in Table 1.1.  
Risk grouping systems are simple to apply in the clinical setting. However, high 
heterogeneity of patients within risk groups inevitably leads to imprecise outcome prediction. 
Multivariable model-based risk classification systems circumvent the problem of collapsing 
patients into broad risk groups by predicting individual risks. Several such models exist in 
prostate cancer, presented as look-up tables (56-59), risk scores (60) or nomograms (61-64). 
Even more complicated risk classification models have been developed using artificial neural 
networks (65-67). In prostate cancer, nomograms have been shown to outperform clinicians 
and simpler risk stratification tools (68, 69) but also the more complicated tools such as 
neural networks (70).  
Table 1.1. Prostate cancer risk stratification criteria for the most commonly used risk grouping systems 
System 
Low risk Intermediate risk High risk 
Very low risk Low risk Favorable Unfavorable High risk Very high 
risk D'Amico (49) PSA≤10 and GS≤6 and  
cT1c-2a 
PSA>10-20 or GS=7 or  
cT2b 
PSA>20 or GS=8-10 or  
cT2c 
EAU (37) PSA<10 and GS≤6 and  
cT1c-2a 
PSA=10-20 or GS=7 or  
cT2b 
PSA>20 or GS>7 or  
cT2c 
NICE (33) PSA<10 and GS≤6 and  
cT1-2a 
PSA=10-20 or GS=7 or  
cT2b 
PSA>20 or GS=8-10 or 
≥cT2c 
GUROC (34) PSA≤10 and GS≤6 and  
cT1-2a 
PSA≤20 and GS≤7 and cT1-2 
not otherwise low-risk 
PSA>20 or GS=8-10 or 
≥cT3a 
AUA (35) PSA<10 and GG1 
and cT1-2a and 
<34% positive 
cores and 0 cores 
with >50% cancer 
and PSAD<0.15 
PSA<10 and 
GG1 and 
cT1-2a 
PSA=10-<20 or GG2-3 or 
cT2b-2c 
PSA≥20 or GG4-5 or 
 ≥cT3 
AUA_i (35) PSA<10 and GG1 
and cT1-2a and 
<34% positive 
cores and no 
cores with >50% 
cancer and 
PSAD<0.15 
PSA<10 and 
GG1 and 
cT1-2a 
GG1 and 
PSA=10-<20 
or 
GG2 and 
PSA<10 
GG2 and 
(PSA=10-<20 
or cT2b-2c) 
or 
GG3 and 
PSA<20 
PSA≥20 or GG4-5 or  
≥cT3 
NCCN (36) PSA<10 and 
GS≤6 and cT1c 
and <3 positive 
cores and ≤50% 
cancer in each 
core and 
PSAD<0.15 
PSA<10 and 
GS≤6 and 
cT1-2a 
PSA=10-20 or 
GS=3+4 or 
cT2b-2c 
and <50% 
positive cores 
PSA=10-20 or 
GS=3+4/4+3 
or cT2b-2c 
PSA>20 or 
GS=4+4/4+5 
or cT3a 
G1=5 or >4 
cores with 
GS=8-10 or 
cT3b-4 
Abbreviations: EAU, European Association of Urology; NICE, The National Institute for Health and Care 
Excellence; GUROC, Genito-Urinary Radiation Oncologists of Canada; AUA, American Urological 
Association; NCCN, National Comprehensive Cancer Network; PSA, Prostate-specific antigen; GS, Gleason 
score; cT, Clinical tumor stage; GG1-5, Gleason grade groups 1-5; PSAD, Prostate-specific antigen density; 
G1, primary Gleason pattern 
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Pretreatment risk stratification tools are developed with the aim of assisting clinicians in 
treatment decision-making for newly diagnosed men. Although they can be developed to 
predict several relevant clinical outcomes, such as progression-free survival or metastasis-free 
survival, prostate cancer death and overall survival are most commonly used for treatment 
decision making. However, most tools have been developed in studies with short follow-up, 
where biochemical recurrence (BCR), rather than prostate cancer death, was used as the 
endpoint (49, 52, 56-61, 63, 64, 67). Although BCR is an imperfect surrogate for prostate 
cancer mortality, only a few of these tools have been validated for prostate cancer death (53, 
71-73). Furthermore, most tools have been developed using cohorts of men treated with 
radical prostatectomy or radiation therapy (49, 52, 56-61, 64, 67), and in selected rather than 
population-based cohorts (49, 52, 56-59, 61, 64).  
Thus, despite the overwhelming number of pretreatment risk stratification tools in prostate 
cancer (74-77), a considerable proportion of men still remain misclassified, and no single tool 
is currently recommended for clinical use. Systematic, head-to-head comparison of the most 
commonly used risk stratification tools with respect to their ability to predict prostate cancer 
death would clarify which tool performs best and should be used to improve treatment 
decision-making. Such a tool could also serve as a baseline model or a “gold standard” used 
to demonstrate independent prognostic value of novel markers. 
1.3 Prognostic markers  
The standard pretreatment markers of prostate cancer prognosis are PSA, cT and Gleason 
score at diagnosis. Although the combination of these markers is the basis for most of the risk 
stratification tools used in clinical practice today, they are not sufficient to capture the 
heterogeneity in the outcomes of localized prostate cancer. Consequently, a plethora of novel 
biomarkers and molecular signatures have been evaluated as predictors of prostate cancer 
prognosis (78-81). Most of these markers are, however, outside of the scope of this thesis and 
will not be addressed in following chapters. 
This thesis focuses primarily on histopathological markers of prostate cancer prognosis. For 
this reason, PSA, cT, the Gleason score and other commonly evaluated histopathological 
markers will be described in more detail.  
1.3.1 Prostate-specific antigen  
PSA is a glycoprotein secreted by prostate epithelial cells that is present in the serum. PSA is 
organ-specific, not cancer-specific, and the PSA level can be increased as a consequence of 
non-cancerous conditions, such as benign prostatic hyperplasia or prostatitis. Baseline PSA is 
a part of risk stratification tools and is commonly used as a marker for monitoring disease 
progression after curative treatment (35, 37, 49, 53, 60, 80, 82, 83). The role of PSA as a 
reliable prognostic marker is not without controversies. PSA levels are subject to large 
analytical and biological variation (84) and the differentiation between indolent and 
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aggressive cancer is sub-optimal as many men with low PSA levels seem to have aggressive 
disease (85).  
1.3.2 Clinical tumor stage 
The Tumor-Node-Metastasis (TNM) system was jointly developed by the American Joint 
Commission on Cancer and the Union for International Cancer Control and is used globally 
as the benchmark for cancer staging (86). The TNM system is a measure of the extent of the 
primary tumor (T stage), spread to lymph nodes (N stage) and distant metastases (M stage) 
(Table 1.2). The cT is based on the digital rectal examination of the prostate (86) and is thus 
quite a subjective measure of tumor extent (Table 1.2). Although magnetic resonance 
imaging is expected to improve the accuracy of cT staging, it appears to have high specificity, 
but poor and heterogeneous sensitivity (87), and is, for now, not recommended as a 
replacement for the digital rectal examination (86).  
Table 1.2. The Tumor-Node-Metastasis (TNM) staging system according to the 8th edition of the American Joint 
Committee on Cancer staging of prostate cancer.  
Stage  Description 
Clinical tumor stage 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically unapparent tumor neither palpable nor visible by imaging 
  T1a Tumor incidental histologic finding in 5% or less of tissue resected 
  T1b Tumor incidental histologic finding in more than 5% of tissue resected 
  T1c Tumor identified by needle biopsy (for example, because of elevated PSA) 
T2 Tumor confined within prostate1 
  T2a Tumor involves one-half of one lobe or less 
  T2b  Tumor involves more than one-half of one lobe but not both lobes 
  T2c Tumor involves both lobes 
T3 Tumor extends through the prostate capsule2 
  T3a Extracapsular extension (unilateral or bilateral) 
  T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles, such as external 
sphincter, rectum, bladder, levator muscles, and/or pelvic wall 
Regional lymph nodes 
NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
1 Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified 
as T1c  
2 Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classified as T2, not T3 
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1.3.3 The Gleason grading system 
In 1966, Dr. Gleason created a 5-point grading system based on the histological patterns of 
prostate cancer (Figure 1.2A) (88). The Gleason score, ranging from 2-10, was defined as a 
sum of the first and the second most common pattern, and it was demonstrated that the 
probability of prostate cancer-specific mortality progressively increased with the increasing 
Gleason score (88, 89). Since then, the Gleason score has been considered one of the most 
powerful prognostic factors in prostate cancer. 
At the time the Gleason grading system was introduced, the Mostofi system, also known as 
the World Health Organization (WHO) grading system, was frequently used for grading 
prostate cancer (90). The WHO grading system was based on cellular anaplasia and the 
degree of glandular differentiation and classified prostate cancers into well differentiated, 
moderately differentiated and poorly differentiated. This system has, however, been entirely 
abandoned in favor of the Gleason grading system. 
1.3.3.1 The evolution of the Gleason grading system 
The Gleason score has undergone a series of changes over time, most notably two major 
revisions by the International Society of Urological Pathology (ISUP) in 2005 (91) and in 
2014 (92).  
The ISUP 2005 revision addressed both the interpretation of the morphological patterns and 
the reporting methods. The most notable changes were recommendations against assigning 
Gleason pattern 1 and 2, narrowing down the definition of Gleason pattern 3 by including 
most of the cribriform glands and poorly formed glands in the definition of Gleason pattern 4, 
and, finally, defining Gleason score as the sum of the most common and the highest Gleason 
pattern (Figure 1.2B). As a consequence, pathologists more often assigned Gleason score 7 
and tumors with Gleason score 6 had better prognosis. This tendency of assigning a higher 
Gleason score over time is known as a grade inflation (93, 94).  
In 2014, the ISUP further modified the definition of the morphological patterns by including 
all cribriform glands and glomeruloid glands in the definition of Gleason pattern 4 (Figure 
1.2C). Furthermore, ISUP endorsed the five-tiered Gleason Grade Groups (GGs) where GG1 
is defined as Gleason score ≤6, GG2 as Gleason score 3+4, GG3 as Gleason score 4+3, GG4 
as Gleason score 4+4, 3+5, 5+3 and GG5 as Gleason score 9-10. The endorsement of the 
GGs was based on the claims that:  
1. The GGs stratify prostate cancer better that the current system (where the current 
system was the three-tiered Gleason score (≤6, 7, 8-10)), 
2. The number of grading categories was reduced from 2-10 to 1-5, 
3. Having GG1 instead of Gleason score 6 as the lowest grade could reduce 
overtreatment of indolent cancers, and  
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4. The GGs are based on the modified Gleason grading system which bears little 
resemblance to the original Gleason grading system (92, 95, 96), which should justify 
it being introduced as a new classification system.  
The ISUP 2014 revision was subsequently adopted by the 2016 WHO classification of 
tumors of the urinary system and male genital organs (97). 
1.3.3.2 Impact of the Gleason grading system revisions on prostate cancer 
prognostication 
The Gleason grading system revisions aimed at improving inter-pathologist agreement and, 
ultimately, prostate cancer prognostication (91, 92, 95). To evaluate improvements in 
prognostication, a direct comparison of the Gleason scores assigned according to the different 
Gleason grading systems is necessary (98). However, only a few studies have compared the 
ISUP 2005 Gleason score to the pre-2005 Gleason score in predicting BCR and found either 
a small (99, 100) or no improvement (101). None of the studies validating the GGs as a 
predictor of adverse outcomes in prostate cancer (see more information under heading 
1.3.3.4.) have also performed a re-review of the same samples according to both the ISUP 
Figure 1.2.  The evolution of the Gleason grading system. Original (pre-2005) Gleason (A), International Society 
of Urological Pathology (ISUP) 2005 Gleason (B) and ISUP 2014 Gleason grading system (C). 
A) Reprinted from Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23:273–
279, with permission from Elsevier; B) and C) Reprinted by permission from Springer Nature Customer Service 
Centre GmbH: Springer Nature, Contemporary Approach to Gleason Grading of Prostate Cancer. In: Prostate 
Biopsy Interpretation by Shah R.B., Zhou M. © 2019. 
C) B) A) 
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2014 Gleason grading criteria and the ISUP 2005 or pre-2005 Gleason grading criteria. Only 
one study has compared the GGs to previous Gleason grading revisions by modelling the 
GGs and the diagnostic Gleason score in predicting BCR, but they did not compare the 
prognostic performance of the two models (102). Thus, even though a plethora of studies 
have unsurprisingly confirmed that the GGs are a prognostic factor in prostate cancer, it is 
still not clear if the changes in the Gleason grading system introduced in 2005 and 2014 have 
improved prostate cancer prognostication.  
1.3.3.3  Inter-observer reproducibility of the Gleason score 
Prior to the ISUP 2005 revision, the agreement for the Gleason score ranged from 0.16 to 
0.70 among uropathologist (103-106) and 0.00 to 0.88 among general urologists (106, 107) 
(Table 1.3). The general opinion was that the ISUP 2005 revision led to an improvement in 
the inter-observer reproducibility (108). This improvement was ascribed to either the more 
specific definition of patterns 3 and 4, or to Gleason score 2-5 no longer being used (94, 99). 
However, the agreement for the ISUP 2005 Gleason score ranged from 0.48-0.68 among 
uropathologists (109-113) and from -0.13-0.68 among general pathologists (110, 113-115), 
indicating no obvious improvement in agreement (Table 1.3). Similarly, the agreement for 
the ISUP 2014 Gleason score ranged from 0.43-0.75 among general pathologists (116, 117), 
while for the GGs it ranged from 0.39-0.75 among general pathologists (116, 117) and 0.48-
0.89 among uropathologists (118) (Table 1.3).  
The lack of obvious improvement in the inter-observer agreement with the ISUP 2005 and 
2014 revisions could be due to the slow adoption of the new grading criteria, different 
interpretations of the guidelines or to differences in study design and methods used to 
quantify the agreement. However, several studies have demonstrated that the agreement can 
be improved by additional training (110), use of reference images (118-120) or various 
techniques for improving reproducibility, such as web-based education or the use of 
interactive digital slides with heat maps (110, 121-123).  
1.3.3.4 Validation of Gleason Grade Groups  
Since the ISUP endorsed the GGs, a plethora of studies have evaluated the ability of the GGs 
to predict BCR (96, 124-132) and/or death from prostate cancer (133-140) (Table 1.4). 
However, most of these validation studies were based on selected samples of treated men 
with a short follow-up. Furthermore, in most of the studies there was no central re-review of 
the diagnostic biopsies according to the ISUP 2014/WHO 2016 criteria. In fact, of four 
studies that had access to centrally re-reviewed diagnostic biopsies (102, 134, 136, 140), only 
one study has done so according to the ISUP 2014/WHO 2016 criteria (102) (Table 1.4).  
Given that none of the validation studies re-reviewed the same samples according to different 
Gleason grading criteria, the claims of better prognostic accuracy of the GGs have been based 
on comparisons with different groupings of the Gleason score, most commonly the three-
tiered Gleason score (≤6, 7, ≥8), and on minimal changes in model discrimination (e.g., 
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change in the second/third decimal of the area under the receiver operating curve 
(AUC)/concordance index (C-index)) (Table 1.4) (98). However, it has also been shown that 
using the GGs seems to result in less upgrading on prostatectomy specimens (102, 141), 
which indicates better identification of potentially aggressive tumors, and, in turn, has great 
clinical implications. 
   
Table 1.3. Inter-observer reproducibility of the Gleason score 
Author Year Sample 
size 
Gleason score Pathologists Inter-observer agreement Kappa type 
No. Type  
McLean (103) 1997      71 Pre-2005   3 Urologic Range: 0.16-0.29 Weighted  
Allsbrook (104) 2001      46 Pre-2005 10 Urologic Range: 0.56-0.70 Weighted  
Allsbrook (107) 2001      38 Pre-2005 41 General 0.44 (Range: 0.00-0.88) Simple  
Glaessgen (105) 2004    2791 Pre-2005   4 Urologic Range: 0.48-0.55 Weighted  
Oyama (106) 2005      37 Pre-2005   8 General 0.49 Simple 
Pre-2005   6 Urologic 0.68 
Melia (111) 2006      81 ISUP 2005   9 Urologic 0.54 (range: 0.49-0.61) Fleiss  
Griffiths (110) 2006      20 ISUP 20057  
24 
General 0.33 Simple  
ISUP 20058  General 0.41 
ISUP 2005 Urologic 0.62 
Veloso (142) 2007    1102 ISUP 20059 
  3 
Mixed12 Range: 0.32-0.44 Weighted  
ISUP 200510 Range: 0.31-0.44 
ISUP 200511 Range: 0.39-0.50 
Mulay (114) 2008      40 ISUP 20057  
  4 
General 0.46 (Range: 0.36-0.65) NR 
ISUP 20058  0.54 (Range: 0.46-0.68)  
Singh (115) 2011      203 ISUP 2005 21 General Range: -0.13 to 0.55 Simple  
Rodriguez-
Urrego (109) 
2011      50 ISUP 2005 
  4 
Urologic 0.54 Simple 
Harnden (113) 2011      20 ISUP 2005   5 Urologic 0.57 Simple 
19 General 0.61 
27 Mixed 0.60 
Goodman (112) 2012 1,9054,5 ISUP 2005   2 Urologic 0.56 (95% CI: 0.48-0.63) Weighted  
Abdollahi (143) 2012    101 Pre-2005   5 NR 0.29  NR 
Abdollahi (122) 2013    150 ISUP 20057  
  3 
NR 0.25 (Range: 0.14-0.39) NR 
ISUP 20058  0.52 (Range: 0.39-0.65) 
Ozkan (116) 2016    1976 ISUP 2014   2 General 0.43 (95%CI: 0.42-0.48) Simple  
GGs   2 0.39 (95%CI: 0.34-0.47) 
Qureshi (144) 2016      47 NR   7 General 0.5 Simple  
Al Nemer (117) 2017    126 ISUP 2014  
  4 
General 0.75 (95%CI: 0.71-0.79) Fleiss  
 GGs 0.75 (95%CI: 0.71-0.79) 
Egevad (118) 2018      904 GGs 23 Expert Range: 0.48 - 0.89 Weighted  
Abbreviations: ISUP, International Society of Urological Pathology; GGs, Gleason Grade Groups; NR, not 
reported  
1 69 patients with 279 slides with cancer 
2 Number of reviewed cores per pathologist not equal 
3 10 biopsy samples, 8 transurethral resection of the prostate (TURP) samples, 2 radical prostatectomy samples 
4 Reviewed using digital microscopy 
5 268 patients with 1,905 slides 
6 407 cores belonging to 34 patients. Tumor was detected in 197 slides (cores) by both pathologists 
7 Before intervention 
8 After intervention 
9 Gleason score calculated as a sum of primary and secondary Gleason pattern 
10 Gleason score calculated as a sum of primary and tertiary (when present) Gleason pattern 
11 The highest core level Gleason score  
12 Two pathologists were experienced in urological pathology and one was less experienced 
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Table 1.4. Gleason Grade Groups validation studies  
Author Population Central 
review 
Outcome1 Comparison Model 
performance 
Period Sample size Treatment 
Leapman (138) 1995-2014 10,529 mixed no PCSM GGs vs. GS (extended)2 - 
Beckmann (133) 2006-2013 4,268 mixed no PCSM GGs - 
Berney (134) 1990-2003 988 WW/early 
hormones 
yes3 PCSM Overall GGs vs. Worst 
GGs 
0.756 vs. 0.752 
Bondarenko 
(124) 
2006-2016 621 RP - robot 
assisted 
no BCR GGs vs. GS (6,7,8-10) 
vs. GS (6,3+4,4+3,8-
10) vs. GS (6,7,8,9-10)  
0.724 vs. 0.740 vs. 
0.730 vs. 0.745  
Chen (135) 2010 13,798 WW/early 
hormones 
no PCSM GGs vs. GS (6,7,8-10) 0.908 vs. 0.907 
Dell’Oglio (125) 2005-2014 1,624 RP no BCR GGs vs. GS (6,7,8-10) 
vs. GS (6,3+4,4+3,8-
10) vs. GS (6,7,8,9-10) 
0.660 vs. 0.653 vs. 
0.656 vs. 0.657 
Epstein (126) 2005-2014 16,172  RP no BCR GGs vs. GS (6,7,8-10) 
vs. GS (6,3+4,4+3,8-
10) vs. GS (6,7,8,9-10) 
0.813 vs. 0.805 vs. 
0.811 vs. 0.806 
He (137) 2006-2012 331,320 mixed no PSCM GGs - 
Kirmiz (127) 2012-2017 8,052 RP no BCR GGs vs. GS (6,7,8-10) 0.76 vs. 0.75 
Loeb (128) 2005-2007 5,880 
RP: 4,325 
RT: 1,555 
RP/RT no BCR  GGs vs. GS (6,7,8-10) 
vs. GS (6,7,8,9-10) 
RP: 0.659 vs. 
0.658 vs. 0.658 
RT: 0.727 vs. 
0.738 vs. 0.730 
Mathieu (129) 2005-2014 27,122 RP no BCR GGs vs. GS (6,7,8-10) 0.743 vs. 0.740 
Offerman (102) 2002-2015 339  
 
RP yes4 BCR GGs vs. diagnostic GS 
(6,3+4,4+3,8,9-10) 
- 
Pierorazio (96) 2004-2011 7,850 RP no BCR GGs - 
Pompe (139) 2004-2009 242,531 
RP: 91,565 
RT: 38,184  
EBRT: 52,926  
NLT: 59,856 
mixed no PCSM  GGs vs. GS (6,7,8-10) RP: 0.813 vs. 
0.804 
RT: 0.731 vs. 
0.727 
EBRT: 0.759 vs. 
0.750 
NLT: 0.817 vs. 
0.810 
Shulman (130) 2005-2015 2,509 RP no BCR GGs - 
Spratt (131) 1994-2013 3,694 RP no BCR GGs vs. GS (6,7,8-10) 0.67 vs. 0.65 
Spratt (140) 1990-2013 847 EBRT yes PCSM GGs vs. GS (6,7,8-10) 0.752 vs. 0.733 
Yeong (132) 2005-2014 638 RP partial5  BCR GGs vs. GS (6,7,8-10) 0.687 vs. 0.647 
Delahunt (136) 2003-2007 496 RT6 yes7 PCSM GGs vs. GS 
(6,7,8,9,10) 
0.782 vs. 0.750 
Abbreviations: PCSM, Prostate cancer-specific death; GGs, Gleason Grade Groups; GS, Gleason score; RP, Radical 
prostatectomy; WW, Watchful waiting; BCR, Biochemical recurrence; RT, Radiation therapy; EBRT, External beam 
radiation therapy; NL, No local therapy 
1 When available, results for prostate cancer specific mortality are reported. Otherwise, results for biochemical recurrence 
are reported.  
2  ≤3 + 3, 3 + 4, 4 + 3, 4 + 4, 4 + 5, 5 + 4, 5 + 5. 
3 Central review according to the Gleason scoring system (Epstein, 2010) 
4 Central review according to the ISUP 2014 criteria 
5 Central review according to the ISUP 2005 criteria of 44 men diagnosed in 2005 
6 Men treated with androgen suppression 6 months prior to radiation therapy and men treated with 12 months of androgen 
suppression after radiotherapy 
7 Central review according to the ISUP 2005 criteria, Gleason score then recoded to GGs 
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1.3.4 Other histopathological markers 
Most men diagnosed with prostate cancer have their diagnosis made on a needle biopsy. 
Prostate cancer biopsy tissue contains a vast amount of information, some of which is 
routinely recorded by pathologists in a pathology report. In addition to the Gleason score, 
pathologists are required to report different measures of tumor extent (i.e., the number of 
positive cores/total number of cores and length of tissue involved by carcinoma in mm or the 
linear extent of prostatic tissue involved by carcinoma as a percentage (%)) and the 
presence/absence of extraprostatic extension (145). Reporting of additional information, such 
as the percentage of Gleason pattern 4 or 4/5, the presence of perineural invasion, and 
intraductal carcinoma, is only a recommendation (145). At ISUP 2014 revision, it was 
additionally recommended to report the GGs for individual cores, the percentage of Gleason 
pattern 4 for cores with Gleason score 7 and the presence of intraductal carcinoma (95). 
Given the need for novel markers that can separate indolent from aggressive cancers, many of 
these routinely reported histopathological features, as well as some features which are not 
routinely reported, have been studied as potential predictors of prostate cancer prognosis 
(146). The most commonly studied histopathological features are described in more detail 
below. 
1.3.4.1 Measures of tumor extent 
Currently, there is no consensus on how to best quantify tumor extent in prostate biopsies. 
Different measures of tumor extent, such as the number or percentage of cores with cancer or 
measures of linear extent of cancer (i.e., total length and percentage of cancer in mm), have 
been evaluated as potential prognostic factors. While the results for the number of cores with 
cancer and total length of cancer are not conclusive (147-151), the results for the percentage 
of cores with cancer and the total percentage of cancer are more consistent. The percentage of 
cores with cancer is an established predictor of BCR (52, 148, 150, 152-155) and has also 
been shown to predict death from prostate cancer (154). Similarly, the total percentage of 
cancer has been repeatedly identified as a predictor of BCR (147, 149, 150, 155, 156) and of 
death from prostate cancer (157, 158). These measures are highly correlated (151, 156) and 
there seems to be no gain in modelling them together (153). Which of the two is a better 
measure of tumor extent is not clear (150, 155, 156).  
When modelled together with other established predictors of prostate cancer prognosis, the 
contribution of both the percentage of cores with cancer and the total percentage of cancer to 
discrimination seems to be minimal (148, 157), which brings their clinical utility into 
question. Nevertheless, some of these measures are already incorporated in risk stratification 
tools and used for clinical decision making. The percentage of cores with cancer and the 
number of cores with >50% cancer involvement separate very low- and low-risk cancer in the 
AUA guidelines (35). The percentage of cores with cancer is also used for pretreatment risk 
stratification using the Cancer of the Prostate Risk Assessment score (CAPRA) score (60), 
and together with the number of cores with cancer and the number of cores with ≤50% cancer 
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involvement in the NCCN guidelines (36). The percentage of cores with cancer, the number 
of cores with cancer, and the number of cores with ≤50% cancer involvement are also a part 
of the criteria for active surveillance (82, 159-161).  
1.3.4.2 Cribriform pattern and intraductal cancer  
Gleason pattern 4 is characterized by four distinct growth patterns: poorly-formed, fused, 
glomeruloid and cribriform pattern (92). Cribriform pattern has been associated with an 
unfavorable biologic behavior, and has often been studied as a potential predictor of prostate 
cancer prognosis (162). The presence of cribriform pattern in radical prostatectomy samples 
has been associated with BCR (162-166) as well as with metastasis after radical 
prostatectomy (164). Cribriform pattern in biopsy samples of men with Gleason score 3+4 
has been shown to predict upstaging (167) and BCR after radical prostatectomy (168).  
Intraductal cancer in radical prostatectomy or biopsy samples has been identified as a 
predictor of BCR (168, 169), clinical progression-free survival (170) and death from prostate 
cancer (169). Given the microscopic similarity of intraductal cancer and cribriform pattern, 
several studies have evaluated the predictive value of the presence of cribriform pattern 
and/or intraductal carcinoma. The presence of cribriform pattern and/or intraductal carcinoma 
in radical prostatectomy samples predicted BCR independently of the Gleason score (171). 
Furthermore, the presence of cribriform pattern and/or intraductal carcinoma on biopsy 
samples predicted death from prostate cancer (172), and incorporating these two patterns into 
the GGs has been shown to somewhat improve discrimination of death from prostate cancer 
compared to the standard GGs (C-index: 0.79 vs. 0.76) (173). 
1.3.4.3 The percentage of Gleason pattern 4  
Both the ISUP 2014 revision and the WHO recommend reporting percentage of Gleason 
pattern 4 for Gleason score 7 prostate cancer in needle biopsies and RP samples (95, 97), 
however, the method for quantification is left optional (95). Different methods for 
quantifying the percentage of Gleason pattern 4 have been studied as potential predictors of 
prostate cancer prognosis, such as the overall percentage of Gleason pattern 4 (total length (in 
mm) of Gleason pattern 4/total length (in mm) of cancer), maximum percentage of Gleason 
pattern 4 in one core, total length (in mm) of Gleason pattern 4 etc. Another potential issue 
regards the cases for which it is recommended to record the percentage of Gleason pattern 4. 
The ISUP 2014 authors stated that they do not record it if any other core has GG5 since 
treatment decision is more straightforward for men with GG5 and the percentage of Gleason 
pattern 4 has little, if any, clinical relevance (95). 
The overall percentage of Gleason grade 4 on both radical prostatectomy and biopsy samples 
has been shown to be an independent predictor of adverse pathology at RP (174-177), BCR 
(166, 174, 176-178) and prostate cancer death among men with GG2 and/or GG3 (179). The 
overall percentage of Gleason grade 4 has been shown to outperform the maximum 
percentage of Gleason pattern 4 (174, 180). However, when modelled with PSA, cT and the 
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percentage of cores with cancer, the total length of the Gleason pattern 4 outperformed both 
the maximum and the overall percent of Gleason pattern 4 in predicting adverse pathology at 
radical prostatectomy (177). 
1.3.4.4 Perineural invasion  
Perineural invasion is a well-known mechanism for the extraprostatic spread of prostate 
cancer (181) and as such has long been recognized as a potential prognostic factor. A plethora 
of studies have evaluated the association between perineural invasion on biopsy or radical 
prostatectomy specimens and BCR, with conflicting results. At least four systematic reviews 
(182-185), of which three include a meta-analysis (182, 184, 185), have confirmed the 
association of perineural invasion with BCR after radical prostatectomy or radiation therapy. 
Nevertheless, the authors still remained cautious when discussing their summary findings due 
to substantial heterogeneity across the evaluated studies and because of the presence of 
selection and publication bias.  
Overall, relatively few studies focus on the prognostic significance of perineural invasion on 
biopsies. A recent study evaluated perineural invasion on biopsies as a predictor of BCR and 
found a 50% increase in the rate of BCR, although with wide confidence intervals (CIs) 
(hazard ratio (HR): 1.55; 95% CIs: 0.98-2.45)  (186). When the authors pooled their results 
with the results from the three largest published studies with similar design, methods and 
research question (187-189), the combined estimate supported perineural invasion on prostate 
biopsy specimens as a strong independent predictor of BCR after radical prostatectomy (186). 
In addition, perineural invasion on prostate biopsy seems to also be a predictor of death from 
prostate cancer (190, 191). These results indicate that perineural invasion should be a 
required component of histopathologic review and it may be relevant for clinical decision-
making in prostate cancer. 
1.4 Digital pathology and virtual microscopy 
Advancements in whole slide imaging technology and software development have led to the 
development of digital pathology and virtual microscopy (192). In digital pathology, glass 
slides are digitalized using a scanner, stored, and viewed locally or transmitted over a 
network for remote viewing on a computer or other electronic devices using a virtual 
microscopy software interface that emulates the light microscopy experience (192-194). 
Digital pathology has mostly been used for education, quality assurance, research, image 
analysis, collaborations and seeking a specialist second opinion (195-197). However, owing 
to recent approvals by the US Food and Drug Administration, digital pathology solutions are 
also starting to be used in clinic practice. 
Several studies have assessed the interchangeability of standard light and virtual microscopy 
in prostate cancer by evaluating the inter-method, intra-observer agreement and/or the intra-
method, inter-observer agreement (109, 113, 198, 199) for several histopathological features, 
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including the Gleason score. The inter-method, intra-observer agreement for the Gleason 
score ranged from 0.49 to 0.77 (109, 198, 199). The inter-observer agreement on light 
microscopy (range: 0.54-0.61) (109, 113) was overall similar to the inter-observer agreement 
on virtual microscopy (range: 0.45-0.62) (109, 112, 113, 199) indicating interchangeability of 
the two methods. One of the well-known downsides of virtual microscopy, which could 
potentially limit the use in clinical practice, is the longer review time (200). However, review 
time will probably be shortened with improvements in software design, and by automating 
several of the most time-consuming parts of slide annotation, such as circling different 
regions of interest. This opens the door for many exciting possibilities, such as using machine 
learning methods for automation. 
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2 Aims of the thesis 
The overarching aim of this thesis is to improve prognostication for men with localized 
prostate cancer through validation of the existing risk stratification tools based on standard 
clinical and histopathological factors, and through validation of the existing, and 
identification of novel, prognostic markers. 
The study specific research aims were: 
Study I. To evaluate if the relative and absolute risks of dying from prostate cancer 
estimated in the competing risk setting using the nested case-control study 
(ProMort I) are comparable to the relative and absolute risks estimated in the 
underlying cohort, and to quantify the bias in the risk estimates. 
To explore alternative approaches for estimating relative and absolute risks in 
the competing-risks setting using the nested case-control study design. 
Study II. To compare the prognostic performance of the most commonly used 
pretreatment risk prediction tools in predicting death from prostate cancer, 
overall and stratified by primary treatment (active surveillance/watchful 
waiting, radical prostatectomy/radiation therapy and androgen deprivation 
therapy) and by year of diagnosis (1998-2002, 2003-2006, 2007-2016). 
Study III. To evaluate if the standard light microscopy and a virtual microscopy system 
which we developed for the central re-review in ProMort I and Study IV can 
be used interchangeably for the histopathological evaluation of prostate 
cancer. 
To evaluate the repeatability (i.e., intra-method, intra-observer agreement) and 
the reproducibility (i.e., intra-method, inter-observer agreement) for different 
key histopathological features in prostate cancer, including the ISUP 2014 
Gleason grading system for both light and virtual microscopy. 
Study IV. To evaluate if the Gleason grading system revisions have improved prostate 
cancer prognostication by comparing the prognostic performance of the pre-
2005 Gleason score and the ISUP 2014 Gleason score in predicting death from 
prostate cancer. 
To evaluate if additional histopathological features (e.g., specific tumor 
features) can further improve the ability to predict death from prostate cancer. 
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3 Materials and methods 
3.1 Data sources 
All the studies in this thesis are based on data from the National Prostate Cancer Register of 
Sweden (NPCR) and Prostate Cancer data Base Sweden (PCBaSe), a research database 
constructed by linking the NPCR to other national registers and demographic databases.  
3.1.1 The National Prostate Cancer Register of Sweden  
The NPCR is a cancer quality register including virtually all incident cases of prostate cancer 
in Sweden since 1998 (201). Compared to the Swedish National Cancer Register, to which 
reporting is mandatory and regulated by law, the NPCR has a 98% coverage (202).  
Data is registered in the NPCR using four registration forms: a diagnostic form, a form for 
subsequent work-up and primary treatment, as well as separate forms for radiation therapy 
(since 2007) and radical prostatectomy (since 2015). The NPCR contains detailed 
information on: 
1. Diagnostic workup (e.g., date and hospital of diagnosis, cause for diagnostic workup 
leading to cancer diagnosis (PSA-screening, lower urinary tract symptoms, other 
symptoms)), 
2. Tumor features (e.g., clinical TNM classification, biopsy tumor differentiation 
(Gleason score or WHO grade), serum PSA level at diagnosis), and  
3. Planned primary treatment (i.e., active surveillance, watchful waiting, radical 
prostatectomy, radiation therapy or primary androgen deprivation therapy) within 6 
months of diagnosis.  
In 2007, the NPCR started registering more detailed information on the biopsy procedure 
(i.e., indicators of tumor extent such as the number of cores taken at biopsy, the number of 
cores with cancer, the total length of all biopsy cores and the total length of cancer in all 
cores), prostate volume and radical prostatectomy and radiation therapy.  
Vital status in the NPCR is updated yearly by linkage to the Swedish Population Register. 
Date and cause of death, coded according to the 10th revision of the International 
Classification of Diseases, are obtained through linkage to the Swedish Cause of Death 
Register. Prostate cancer specific death is defined as death where prostate cancer was coded 
as the underlying cause of death. For more information on the registers used in this thesis, 
recorded information, their coverage and validity, please see Table 3.1.  
3.1.2 Prostate Cancer data Base Sweden  
In 2008, the Swedish personal identity number was used to link NPCR to a number of 
national population-based health-care registers and demographic databases, and construct a 
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research database named PCBaSe (201, 203). The NPCR was first linked to the Swedish 
Cancer Register, the Total Population Register and the Cause of Death Register, and, 
subsequently, to the National Patient Register, the Prescribed Drug Register, the Longitudinal 
Integration Database for Health Insurance and Labour Market Studies (LISA) (Table 3.1) as 
well as several other national (quality) registers (203). The PCBaSe linkages are updated 
every three years.  
3.2 Study designs, study populations and covariate information 
3.2.1 Study I  
In Study I, we used a case-control sample from the NPCR, called ProMort I. ProMort I is an 
ongoing study which aims to identify tissue-based, molecular biomarkers of death from 
prostate cancer for men with low- or intermediate-risk prostate cancer. As this thesis focuses 
on clinical and histopathological markers of prostate cancer, ProMort I was used only to 
evaluate if the nested case-control design can be used to evaluate absolute risks of dying from 
prostate cancer in the competing risks setting. Furthermore, as a part of ProMort I, we 
developed a virtual microscopy system which was used in Study III and Study IV (for more 
details see the section 3.4.2.1). 
Table 3.1. Overview of the registers and databases providing data for PCBaSe. Only the registers from which 
information was used in this thesis are presented. 
Registry Recorded information Coverage Update 
The Swedish Cancer 
Register (204) 
Personal information, medical data (e.g., date and bases for 
diagnosis, tumor site, histological type, stage) and follow-up 
data (date and cause of death, migration date) 
96%1 (205) Annual 
The Total Population 
Register (206, 207) 
Personal information, birth-related data (e.g., date and 
country), address data, income, citizenship, country of 
immigration/emigration, and dates of death and 
immigration/emigration 
0.25-0.5%2 
(207) 
Daily 
The Cause of Death 
Register (13, 208) 
Personal information, birth-related data, date of death, 
underlying and contributing cause(s) of death, information 
on autopsy and surgery within 4 weeks prior to death 
for PCa3:  
86-96%  
(209, 210) 
Annual 
The National Patient 
Register (204) 
Personal patient information, geographical data, 
administrative data (e.g., inpatient (IP) and outpatient (OP) 
date of admission and discharge), medical data (e.g., main 
and secondary diagnosis, procedures) 
IP: 100%  
(211) 
OP: 80% 
Monthly 
LISA (212, 213) Personal and family-related demographic data, civil status, 
birth-related data, data on immigration/emigration, highest 
level of education, data on occupation, employment status 
and income, and socioeconomic indices 
NA Annual 
Abbreviations: LISA, Longitudinal Integration Database for Health Insurance and Labour Market Studies; NA, 
Not available 
1 The estimated capture rate of all cancers to the Swedish Cancer Registry compared with the National Patient 
Register 
2 The estimated over-coverage 
3 86-96% refers to agreement with cause of death determined by a medical record review 
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ProMort I was nested among all men in the NPCR diagnosed with low- or intermediate-risk 
prostate cancer between January 1, 1998 and December 31, 2011. We defined low- or 
intermediate-risk prostate cancer as cT1-2, Gleason score ≤7 (or WHO grade 1 when 
information on the Gleason score was missing), serum PSA<20 ng/mL, and no signs or non-
assessed status of lymph node (N0 or Nx) or distant (M0 or Mx) metastases. Of 
approximately 130,000 men in the NPCR, 57,952 men fulfilled these criteria. Follow-up was 
available until December 31, 2012. All men who died from prostate cancer during follow-up 
(n=1,735) were selected as cases. For each case, we randomly selected one control, matched 
on year and hospital of diagnosis. The control had to be alive at the date of death of the 
respective case. Cases without an eligible control within the matching stratum (n=25) were 
excluded from the study. The final ProMort I data set included 1,710 cases and 1,710 
controls. 
Information on age, cT, Gleason score/WHO grade and PSA at diagnosis, as well as vital 
status and cause of death, was abstracted from the NPCR. We assigned Gleason score ≤6 to 
140 cases and 103 controls with WHO differentiation grade 1 and no information on the 
Gleason score.  
3.2.2 Study II 
Study II is a cohort study including all men in PCBaSe 4.0 (the fourth update of PCBaSe), 
who were diagnosed with non-metastatic (i.e., not M1 or N1) prostate cancer between 
January 1, 1998 and December 31, 2016 (n=154,811). Follow-up was available until 
December 31, 2016. Prostate cancer death was used as the main outcome.  
Information on age, PSA, clinical TNM stage, primary and secondary Gleason pattern, 
Gleason score and tumor extent at diagnosis was abstracted from PCBaSe, and used to define 
the risk stratification tools assessed in this study: 
1. Risk group systems (D’Amico (49), NICE (33), GUROC (34), AUA (35), EAU (37), 
NCCN (214) and the Cambridge Prognostic Groups (CPG) (53)) (see also Table 1.1), 
2. Risk scores (CAPRA score (60)), and 
3. Nomograms (pre-operative Memorial Sloan Kettering Cancer Center (MSKCC) 
nomogram (83)).  
We also abstracted information on planned primary treatment, year of diagnosis, Charlson 
Comorbidity Index, marital status and education level from PCBaSe. 
Missing values for the variables included in the risk stratification tools were imputed using 
multivariate imputation by chained equation (215, 216). Information on cT2-3 sub-stage (i.e., 
cT2a, cT2b, cT2c, cT3a, cT3b) is not recorded in PCBaSe and could not be imputed. Instead, 
we used a cohort of men diagnosed with prostate cancer between 1995 and 2015 who were 
treated with proton-boost radiation therapy at the Uppsala University Hospital, Uppsala, 
Sweden (217) to develop regression models predicting the probability of cT2 and cT3 sub-
stage. These models were then used to predict the probability of cT2 and cT3 sub-stage for 
 20 
each study subject in PCBaSe with known cT2 or cT3 stage, respectively. Each patient was 
assigned the cT2 or cT3 sub-stage category with the highest predicted probability.  
3.2.3 Study III and IV 
Study III is a reliability/measurement study conducted in a subsample (N=60) of Study IV 
with the aim of validating an internally developed virtual microscopy system used for central 
re-review in ProMort I and Study IV. Study IV is a case-control study nested in the NPCR, 
named ProMort II.  
Exclusions Case Control 
Diagnostic slides not retrieved 53 48 
Diagnosis based on cytology 41 23 
Duplicate subjects 1 3 
 
Exclusions Case Control 
No evaluable slides 19 34 
Rejected at clinical annotation 1 6 
No cancer 8 13 
 
Exclusions Case Control 
Missing clinical M-stage in the 
NPCR, M1 in the medical chart 
1  
Missing PSA 2 2 
Missing primary treatment 1 1 
Missing clinical T-stage 4 4 
Complete separation 2  
 
Light vs. virtual microscopy 
N=60 
ProMort II 
(500 cases/500 controls) 
N=830 
(404 cases/426 controls) 
N=7532 
(377 cases/379 controls) 
N=7362 
(367 cases/369 controls) 
N=62,603  
(NPCSM =8,076 died from PCa)1 
All men with non-M1 PCa in NPCR (1998-2015) 
N=146,137 (NPCSM=18,022)1 
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Not in: Dalarna, Gävleborg, Halland, Jönköping, 
Kalmar, Kronoberg, Norrbotten, Skåne, Värmland, 
Västmanland, and Örebro (N=83,534) 
Figure 3.1. Flow chart of the selection of cases and controls for Study III and IV 
Abbreviations: PCa, Prostate cancer; NPCSM, The number of men who had died from prostate cancer; NPCR, 
the National Prostate Cancer Register of Sweden 
1 Based on the data extracted from NPCR June 5, 2020, but restricted to match conditions at April 11, 2017, 
when ProMort II was sampled 
2 Includes duplicate subjects (cases selected as controls (n=1) and controls selected more than once (n=3))  
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ProMort II cases and controls were selected from all men in the NPCR who were diagnosed 
with non-metastatic prostate cancer (i.e., not M1) between January 1, 1998 and December 31, 
2015. Given that all diagnostic slides belonging to the selected cases and controls were to be 
centrally re-reviewed by the study pathologists, cases and controls were selected from 11 (out 
of 21) counties in the NPCR deemed most likely to respond to our request for slides (Dalarna, 
Gävleborg, Halland, Jönköping, Kalmar, Kronoberg, Norrbotten, Skåne, Värmland, 
Västmanland, and Örebro). Follow-up was available until December 31, 2015. Of all men 
who had died from prostate cancer by the end of the follow-up we randomly selected 500 
cases and matched them to 500 men who had not died from prostate cancer (controls) by year 
and county of diagnosis. Controls had to be alive at the date of death of the respective case. 
The complete selection process is described in Figure 3.1. 
Information on age, PSA, clinical TNM stage, primary and secondary Gleason pattern, and 
the Gleason score at diagnosis, as well as planned primary treatment, was abstracted from the 
NPCR. In addition, for the 404 cases and 426 controls for whom we had successfully scanned 
the diagnostic slides, we performed a medical chart review to extract detailed information on 
the clinicopathological features at diagnosis, biopsy procedure, primary treatment, pathology 
after radical prostatectomy, BCR, castration resistance, metastasis and death. Medical charts 
were successfully reviewed for 282 cases (69.8%) and 297 controls (69.7%). The extracted 
information was used when information abstracted from the NPCR was missing.  
3.2.3.1 Slide digitalization and managing 
We first retrieved the diagnostic biopsy slides from the Pathology wards across Sweden. Out 
of the 1,000 sampled men, the diagnostic slides belonging to 830 men (83%), 404 cases and 
426 controls, were retrieved (Figure 3.1). The slides were then scanned at the Örebro 
University Hospital, Örebro, Sweden, using a Pannoramic 250 Flash II digital slide scanner 
(3DHistech Ltd., Budapest, Hungary) with a 40x objective. Scanned images had a resolution 
of 0.19 microns/pixel. In total, we scanned 5,536 slides.  
After the scanning, the images were uploaded to a virtual microscopy system developed by 
the Centre for Advanced Studies, Research and Development in Sardinia (CRS4), Pula, Italy 
as a part of the ProMort I study (218). The virtual microscopy system is composed of two 
integrated components (Figure 3.2):  
1. Ome_seadragon (https://github.com/crs4/ome_seadragon), a plugin for the Open 
Microscopy Environment Remote Objects (OMERO) platform (219) which enables 
viewing, handling and annotation of the 3DHistech images. The image management 
is based on the OMERO.server which supports over 140 different image formats and 
allows for storing of meta-information (e.g., classification TAGs or Regions of 
Interests (ROIs)). The ome_seadragon simplifies the integration of the images stored 
within OMERO into external web systems (220), adds Deep Zoom Image format 
support to OMERO and, through OpenSlide libraries (https://openslide.org), increases 
the number of supported image formats. The user side of ome_seadragon is a 
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specialized viewer developed from the open source viewer OpenSeadragon 
(https://openseadragon.github.io). Real time annotation tools which are based on 
paper.js libraries (http://paperjs.org) enable navigation through Whole Slide Imaging 
(WSI) and annotation by drawing different 2D shapes, as well as taking precise 
measures (e.g., ROI length or area). 
2. The ProMort Image Management System (https://github.com/crs4/ProMort), a 
clinical annotation platform which manages the review worklist and clinical 
annotation process (i.e., definition and clinical annotation of ROIs). This software 
embeds the ome_seadragon plugin and allows users to navigate and annotate digital 
slides while acquiring the ROIs. Clinical annotations are performed via a dedicated 
user interface which has been designed specifically for ProMort. 
Both components are web-based applications developed to run on all modern browsers and 
require no specific hardware or operative system. The pathologists involved in the study 
(Michelangelo Fiorentino and Francesca Giunchi) used either a desktop PC, with a 22 inch 
Olivetti OLISCREEN22 display, running the Google Chrome browser or a 2018 iPad Pro, 
with a 12.9 inch display, running the Safari browser.  
 
Figure 3.2. A simplified schematic representation of the virtual microscopy system developed by the Centre for 
Advanced Studies, Research and Development in Sardinia (CRS4), Pula, Italy, which was used for the central 
re-review in ProMort I and ProMort II  
 
 
ProMort application handles 
user secure authentication, 
worklists management, all the 
image-related data (quality 
control and ROIs) and clinical 
classification of the slides. 
ProMort retrieves data of the tiles 
that compose the image and 
shows them to the user using the 
ome_seadragon web viewer. 
Omero server 
+ 
Ome-seadragon app 
To improve performance, 
tiles can be stored in a cache. 
Ome_seadragon app provides callbacks needed 
by OpenSeadragon to access OMERO images 
as images in Deep Zoom Image (DZI) format. 
ProMort’s user interface encloses ome_seadragon plugin to 
display images. The plugin directly communicates with the 
OMERO server. 
Users can manage their worklists and regions of interest (ROIs) 
on the images and classify them using the web application. 
ProMort server 
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3.2.3.2 Histopathological review 
The two study pathologists, with 6 and 13 years of experience respectively as dedicated 
genitourinary pathologists, performed the re-review of all scanned images according to the 
2016 WHO classification of tumors of urinary system and male genital organs (97). The 
pathologists were blinded to the case-control status and to the original clinical and 
histopathological information of all slides. 
We first selected 60 random cases and controls out of the 830 men in ProMort II whose 
diagnostic slides had been successfully scanned. The selected men were diagnosed in Örebro 
county (n=25) and Värmland county (n=35) (Figure 3.1). Slides belonging to these 60 men 
were used in Study III to evaluate the interchangeability of standard light microscopy and the 
above-described virtual microscopy system. The study pathologists reviewed all cores 
belonging to the 60 selected men using both light and virtual microscopy according to a pre-
specified protocol (Figure 3.3). Using this protocol allowed us to estimate the intra- and inter-
observer agreement for both light and virtual microscopy. 
Slides belonging to the remaining 770 subjects were subsequently reviewed only by one 
pathologist. In total, 8,982 cores belonging to 770 subjects were reviewed, of which 3,713 
cores belonging to 749 subjects contained cancer (Figure 3.1). A mock-up example of the 
review process is presented in the Figure 3.4. The features recorded during the re-review are 
presented in Table 3.2. Case level summaries were calculated as the sum across all cores for 
continuous features, and as presence or absence in at least one of the cores for binary features. 
The highest core-level GGs/Gleason score was used as an overall GGs/Gleason score for a 
case. 
 
Figure 3.3. Pre-specified review protocol for evaluation of interchangeability of light and virtual microscopy 
Pathologist 2 
Light 
Microscopy 
Virtual 
Microscopy 
2 weeks 
Light 
Microscopy 
Virtual 
Microscopy 
2 weeks 
Light 
Microscopy 
Virtual 
Microscopy 
2 weeks 2 weeks Pathologist 1 
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3.2.3.3 Pre-2005 Gleason grading 
To approximate the pre-2005 Gleason grading we used information on cribriform pattern, 
poorly formed glands and hypernephroid pattern. Gleason pattern 4 (primary or secondary) 
was downgraded to Gleason pattern 3 whenever Gleason pattern 4 was assigned based on the: 
1. Cribriform pattern only,  
2. Poorly formed glands only and  
3. Cribriform pattern and/or poorly formed glands.  
In all three definitions hypernephroid pattern was graded as Gleason pattern 4. The pre-2005 
Gleason score for each core was then calculated as the sum of the back-transformed primary 
and secondary Gleason pattern.  
Table 3.2. Histopathological features recorded by the pathologists during the central re-review 
Recorded for: Feature Unit 
Core Length microns 
 Area squared microns 
 Cancer yes/no 
Core with cancer Length microns 
 Area squared microns 
 Primary Gleason pattern 3-5 
 Secondary Gleason pattern 3-5 
 ISUP 2014 Gleason score 6, 3+4/4+3, 8, 9, 10 
 Gleason Grade Groups 1-5 
 Poorly formed glands yes/no 
 Cribriform pattern yes/no 
 Hypernephroid pattern yes/no 
 Comedonecrosis yes/no 
 Small-cell/signet ring cell-like cancer yes/no 
 Perineural invasion yes/no 
 Intraductal carcinoma yes/no 
 Ductal carcinoma yes/no 
 Mucinous carcinoma yes/no 
Core with Gleason score 7 Area of Gleason pattern 41,2 squared microns 
Slide Acute inflammation yes/no 
 Chronic inflammation yes/no 
 Periglandular inflammation yes/no 
 Intraglandular inflammation yes/no 
 Stromal inflammation yes/no 
 High-grade prostatic intraepithelial neoplasia (HGPIN) yes/no 
 Post-atrophic hyperplasia (PAH) yes/no 
Abbreviations: ISUP, International Society of Urological Pathology 
1 The percentage of Gleason pattern 4 was calculated as (area of Gleason pattern 4/tumor area)*100 
2 On light microscopy, the percentage of Gleason pattern 4 was assessed by “eye-balling” and categorized as 
<10, 10-19%, 20-29% etc.) 
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As a secondary approach, we used the diagnostic Gleason score recorded in the NPCR and in 
medical charts as the pre-2005 Gleason score. This approach was restricted to men diagnosed 
with prostate cancer before 2006. 
3.3 Methodological considerations and statistical methods 
Study I is a method application study that deals with some of the challenges related to the 
nested case-control study design. Given the non-standard methodology, the methods section 
for this study will be described in more detail. In Study II-IV we used standard methodology, 
and only a short summary of the statistical methods will be given here.  
3.3.1 Study I 
Given the difficulty in separating indolent from aggressive prostate cancer, especially for men 
with low- and intermediate-risk disease, we intended to use ProMort I to not only identify 
novel molecular markers of prostate cancer prognosis, but also to build a new prognostic 
model, or update an existing one. To be clinically useful, a prognostic model needs to be able 
to predict the absolute risk of the outcome of interest given the different combinations of the 
predictor values. Relative risks (e.g., odds ratios (ORs), risk ratios or HRs) are not directly 
interpretable and are used only to obtain absolute risks of the outcome.  
To use ProMort I for prognostic modelling, we needed to deal with two issues: 
1. Competing risks – men diagnosed with prostate cancer are on average old and, given 
the prolonged natural history of prostate cancer, especially among men with low- and 
intermediate-risk disease, they are more likely to die with, rather than from, prostate 
cancer.  
2. Study design – the best design for prognostic modelling is a prospective cohort study. 
However, ProMort I is a nested case-control study. 
Nested case-control studies are typically used for the estimation of relative risks. However, if 
adequate methods are used, nested-case control studies can be used to obtain unbiased 
estimates of absolute risks (221-226). These methods have also been extended to a setting 
where secondary outcomes are of interest (227, 228), and to the competing risk setting (229, 
230). 
3.3.1.1 Competing risks 
In Study I, we focused on the cause-specific hazards approach for dealing with competing 
risks (231, 232) as the way controls were selected in ProMort I precluded the use of other 
approaches, such as the subdistribution hazards approach (233, 234).  
The presence of competing risks implies that a subject is at risk of having 𝐾 different events. 
In this setting, the cause-specific hazard function, 𝜆𝑘(𝑡), represents the instantaneous risk of 
dying from the event 𝑘 given that the subject is still alive at time 𝑡:  
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𝜆𝑘(𝑡) = lim
∆𝑡→0
𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡, 𝐾 = 𝑘|𝑇 ≥ 𝑡)
∆𝑡
 
The cumulative incidence function (CIF) for the event of interest 𝑘 (i.e., prostate cancer 
death), 𝐼𝑘(𝑡), is a function of the cause-specific hazard for both the event of interest and the 
competing event(s) (i.e., death from other causes). 𝐼𝑘(𝑡) is defined as the probability of dying 
from the event 𝑘 at the time 𝑡 given that the subject can die from other causes: 
𝐼𝑘(𝑡) = ∫ 𝜆𝑘(𝑢)∏𝑆𝑘(𝑢)𝑑𝑢
𝐾
𝑘=1
𝑡
0
 
3.3.1.2 Estimation of absolute risks (CIFs) 
To estimate the absolute risks using ProMort I, we used the inverse probability weighting 
method proposed by Samuelson (225). This method has been described in the context of the 
partial likelihood which is used to estimate parameters in the Cox proportional hazards model 
(235). In the partial likelihood, the baseline hazard function is not specified, and in order to 
estimate it we would need to use additional estimators, such as the Breslow estimator (235). 
Since we were interested in estimating both the HRs and the CIFs in Study I, we decided to 
use flexible parametric survival models instead of the Cox proportional hazards model (236, 
237). In flexible parametric survival models, the baseline hazard function is fully specified 
and estimated by maximizing the full likelihood (236, 237).  
Thus, to estimate CIFs in ProMort I, we used the weighted full likelihood method where the 
weights for cases and controls equal the inverse of their selection probability. In nested case-
control studies, typically, all cases are sampled and their weight equals one. Given that the 
proportion of eligible cases which were not included in ProMort I was very small (1.5%), all 
cases were assigned with a weight of one. The selection probability for a control 𝑖, 𝑝𝑖, was 
calculated using an extension of the method proposed by Samuelson (225) which accounts 
for the presence of ties in failure times and for additional matching (221, 227):  
𝑝𝑖 = 1 − ∏ (1−𝑚𝑖𝑛 (1,
𝑚𝑏𝑗𝑖
𝑛𝑗𝑖 − 𝑏𝑗𝑖
))
𝑗:𝑎𝑖≤𝑇𝑗≤𝑇𝑖
 
At each event time 𝑇𝑗, a subject 𝑖 who entered the study at time 𝑎𝑖 (𝑎𝑖 ≤ 𝑇𝑗), was censored or 
failed at time 𝑇𝑖 (𝑇𝑖 ≥ 𝑇𝑗), and who satisfied the matching criteria, could be sampled as a 
control. 𝑚 is the number of controls selected per case at each event time 𝑇𝑗. 𝑛𝑗𝑖 is a risk set at 
time 𝑇𝑗 which satisfied the matching criteria and 𝑏𝑗𝑖 is the number of tied subjects that failed 
at the time 𝑇𝑗 who satisfied the matching criteria. 
The weights, 𝜔𝑖, are defined as: 
𝜔𝑖 =
1
𝑝𝑖
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Of note, in this type of analysis, matching is broken and all unique individuals are pooled for 
the analysis (224). For controls who were selected more than once, we kept only one control 
record. For a control who later became a case, we kept only the case record.  
3.3.1.3 Statistical analyses 
We first estimated HRs and CIFs in ProMort I using the above-described inverse probability 
weighting approach. The flexible parametric model was fitted as described by Hinchliffe et 
al. (236). The cause-specific HRs and the corresponding 95% CIs of death from prostate 
cancer and death from other causes were estimated simultaneously (237, 238), and the CIFs 
were obtained by combining the cause-specific HR estimates (239). The HRs and CIFs 
estimated in ProMort I were compared to the HRs and CIFs estimated in the NPCR. 
Then we used two extensions of the inverse probability weighting approach to the setting 
with more than one endpoint, including competing risks, where: 
1. Both the competing risk cases and the competing risk controls were augmented 
(“Method 1”) (240), and  
2. Only the competing risk cases were augmented (“Method 2”) (229). 
The main idea behind the two methods is to reuse the controls and the cases selected for one 
endpoint as controls in the analysis of another endpoint, with or without a new control 
selection. The HRs and CIFs estimated using these two alternative approaches were also 
compared to the estimates from the NPCR. 
Finally, we evaluated the bias in the HRs and CIFs estimated in ProMort I using the inverse 
probability weighting approach. To do so, we used the same selection criteria as for ProMort 
I to draw 1,500 random nested case-control subsamples from the NPCR. The bias in the 
log(HRs) was calculated as the absolute difference in the log(HRs) estimated in the 1,500 
subsamples and the log(HRs) estimated in the NPCR. We also calculated the bias in CIFs of 
dying from prostate cancer at 5, 10 and 15 years of follow-up, as well as the coverage 
probability of their 95% CIs. The bias in CIFs was defined as the absolute difference in CIFs 
estimated in the 1,500 subsamples and CIFs estimated in the NPCR.  
3.3.2 Study II 
In Study II, we initially planned to use PCBaSe 4.0 to formally externally validate the most 
commonly used prostate cancer risk stratification tools. External validation and comparable 
information on each tool’s ability to predict prostate cancer death in untreated patients are key 
for informed decision-making in clinical practice.  
Formal external validation is not possible without having information on the intercept (i.e., 
baseline survival function in models analyzing time-to-event) and the linear predictor from 
the original prognostic model (241, 242). However, for most of the risk stratification tools 
evaluated in this study, information on the intercept and/or the linear predictor from the 
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original models has not been published. Furthermore, most of the risk stratification tools have 
been developed or validated to predict BCR and not prostate cancer-specific death. We were 
thus not able to perform a formal external validation. Instead, we re-estimated the linear 
predictor for each risk stratification tool in PCBaSe and performed a head-to-head 
comparison of their prognostic performance in predicting prostate cancer death.  
3.3.2.1 Statistical analyses 
The prognostic performance of the different risk stratification tools was evaluated using a 
split-sample approach. The linear predictor for each risk stratification tool was re-estimated in 
the training dataset and the models were internally validated in the testing dataset. 
We used the cause-specific hazards approach to account for the presence of competing 
events. The cause-specific HRs and 95% CIs for prostate cancer death and death from other 
causes were estimated using the Cox proportional hazards model (235). Time at risk was 
calculated from the date of diagnosis until the date of death, emigration or end of follow-up 
(December 31, 2016), whichever came first. The models predicting death from prostate 
cancer included only the risk grouping system, while the models predicting death from other 
causes also included age and year of diagnosis, the Charlson Comorbidity Index, marital 
status, education level and primary treatment. The cause-specific hazards for prostate cancer 
death and death from other causes were then combined to obtain the CIFs for prostate cancer 
death (243). 
Model performance was evaluated in terms of discrimination and calibration. Discrimination 
was evaluated by the C-index adapted for competing risks (244, 245) in the full training 
datset, and stratified by primary treatment (active surveillance/watchful waiting, radical 
prostatectomy/radiation therapy and androgen deprivation therapy) and by year of diagnosis 
(1998-2002, 2003-2006, 2007-2016). The C-index was estimated by truncating the maximum 
follow-up time in the testing datasets at 1-19 years of follow-up. Calibration was evaluated by 
comparing the non-parametric CIFs (243) with the mean predicted CIFs at 5, 10 and 15 years 
of follow-up. 
Of note, since multiple imputation was used to deal with the missing covariate information, 
the HRs, CIFs and C-indices for each risk stratification tool were combined across the 
imputed datasets (246). 
3.3.3 Study III 
In Study III, we assessed the repeatability (i.e., intra-observer agreement) and reproducibility 
(i.e., inter-observer agreement) of the ISUP 2014/WHO 2016 Gleason grading system 
evaluated on light microscopy and the virtual microscopy system which was developed for 
central re-review in ProMort I and ProMort II. The intra- and inter-observer agreement were 
evaluated within and between the two microscopy methods.  
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The agreement was evaluated using Cohen’s kappa (κ) for binary variables (247), weighted 
Cohen’s kappa (κw) with linear weights for ordinal variables (248), and Bland and Altman’s 
limits of agreement for continuous variables (249). For descriptive purposes, κ/κw<0 was 
considered as no agreement, 0–0.20 slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 
substantial, and 0.81–1 as almost perfect agreement (250).  
3.3.4 Study IV 
In Study IV, we conducted two separate analyses. Both analyses were performed using all 
subjects with complete information on all covariates (Figure 3.1).  
We first evaluated if the Gleason grading system revisions have improved prostate cancer 
prognostication by comparing the prognostic performance of the pre-2005 Gleason score and 
the ISUP 2014 Gleason score in predicting death from prostate cancer. The pre-2005 Gleason 
score was approximated using two approaches. In the first approach, we back-transformed the 
ISUP 2014 Gleason score into the pre-2005 Gleason score as described in the section 3.2.3.3. 
In the second approach we used the diagnostic Gleason score restricted to all men diagnosed 
before 2006. ORs and 95% CIs of the association between the pre-2005 Gleason score and 
the ISUP 2014 Gleason score and death from prostate cancer were estimated using 
unconditional logistic regression adjusted for the matching variables (year and county of 
diagnosis, and follow-up time) and primary treatment. Multivariable models included 
untransformed age, PSA (transformed using restricted cubic splines with knots at 4.5, 16 and 
105.65 ng/ml) and cT at diagnosis.  
In the second analysis, we evaluated if additional histopathological features are independent 
predictors of death from prostate cancer. As above, ORs and 95% CIs of the association 
between each histopathological feature and death from prostate cancer were estimated using 
unconditional logistic regression adjusted for the matching variables and primary treatment. 
We then evaluated if each histopathological feature predicts death from prostate cancer 
independently of GGs, and, finally, independently of GGs, age, PSA and cT at diagnosis. We 
also explored the presence of statistical interaction with the GGs. 
The prognostic performance for different models was evaluated by calculating the AUC 
(251). As a sensitivity analysis, we repeated all the analyses using conditional logistic 
regression. 
3.4 Ethical considerations 
In this thesis, we used information from registries, medical charts and diagnostic slides, all of 
which contain sensitive personal information. In case of release of sensitive data for research, 
all participants should be re-contacted. However, in large-scale research, re-contacting might 
not always be practicable, feasible or even possible. Many of the involved patients may no 
longer be alive and non-response could threaten study validity. For all the studies in this 
thesis, the Research Ethics Committee concluded that the potential benefits for the 
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community outweigh the potential risks and the requirement for consent was waived. Since 
potential risks included violation of individual patient privacy, handling of sensitive data 
needed to be given the highest consideration. Below I will describe precautionary measures 
taken to minimize the risk of violation of individual patient integrity. 
For the purpose of Study I and Study II, access to the registry data (i.e., the NPCR and 
PCBaSe) was possible only through the NPCR server in Uppsala, Sweden. The NPCR server 
has a very strict import/export policy and the risk for violation of individual patient privacy 
was very low. All men in ProMort I and ProMort II datasets, which were used in Study I, III 
and IV, were assigned a study-specific identification number by the NPCR upon the release 
of the data. Pseudonymized ProMort I and ProMort II data was then stored on a secure server 
at the Clinical Epidemiology Division at Karolinska Institutet, Stockholm, Sweden and 
handled according to the institution’s guidelines for information security.  
For ProMort I and ProMort II we performed a centralized re-review of the diagnostic slides, 
and for ProMort II additional information was extracted from the medical charts. For this 
reason, the key between a study-specific identification number and the personal identification 
number could be accessed by selected collaborators. For each man, the diagnostic slides and 
the medical charts were obtained from the diagnostic hospital/pathology ward and sent to 
Örebro University Hospital, Örebro, Sweden. After the diagnostic slides were scanned and 
the information was abstracted from the medical charts, personal identification numbers were 
replaced by the study-specific identification numbers and the slides and chart were returned 
to the respective institutions. The de-identified images were sent to the CRS4, Pula, Italy, and 
securely stored on the CRS4 server. The images were assigned with another random 
identification number at the time of histopathological review. Data extracted from the 
histopathological review and the data extracted from the medical charts were kept on the 
server at the Clinical Epidemiology Division at Karolinska Institutet and handled according 
to the institution’s guidelines for information security.  
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4 Results 
Brief summary of the results: 
Study I. The relative risks of dying from prostate cancer estimated using the nested 
case-control study design were, as expected, comparable to the estimates from 
the underlying cohort. The estimates of the relative risks of dying from other 
causes were, however, biased, which introduced bias in the estimates of the 
absolute risks of dying from prostate cancer in the competing-risks setting.  
Study II. The pretreatment risk stratification tools that performed best in predicting 
death from prostate cancer were the MSKCC nomogram, CAPRA score and 
CPG system. These tools discriminated best regardless of the primary 
treatment and year of diagnosis. 
Study III. The repeatibility and reproducibility of the ISUP 2014 Gleason grading 
system within and between light and virtual microscopy was good. The 
repeatability and/or reproducibility for some of the rare, or rarely reported, 
features (e.g., intraductal cancer, inflammation, HGPIN and PAH), as well as 
for the percentage of Gleason pattern 4, was poor.  
For all evaluated features, the agreement was similar within and between light 
and virtual microscopy which indicates interchangeability of light microscopy 
and our internally developed virtual microscopy system for the 
histopathological evaluation of prostate cancer.   
Study IV. The ISUP 2014 Gleason score discriminated death from prostate cancer better 
than the pre-2005 Gleason score, likely due to classifying all cribriform 
patterns, rather than poorly formed glands, as Gleason pattern 4. In addition, 
comedonecrosis and HGPIN predicted death from prostate cancer 
independently of the GGs, age, PSA and cT at diagnosis. 
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4.1 Study I 
In Study I, we evaluated if the nested case-control study design (ProMort I) can be used to 
estimate the relative and absolute risks of dying from prostate cancer in the competing risks 
setting.  
When we compared the relative risks of dying from prostate cancer in ProMort I to those in 
the NPCR, the point estimates were overall similar (Figure 4.1A) and the mean absolute bias 
was generally close to zero for all covariates. The point estimates for death from other causes 
were, however, generally biased for ProMort I (Figure 4.1B) with the largest mean absolute 
bias for age (−3.813, −0.118, and 0.118 for ages ≤55.0 years, 65.1–75.0 years, and >75.0 
years, respectively). Only a few subjects in the age ≤55.0 category had died from other causes 
and were sampled in ProMort I, leading to extreme and unreliable estimates.  
 
The 5-, 10-, and 15-year CIFs of death from prostate cancer were, overall, similar in ProMort 
I and the NPCR. However, the bias in the ProMort I estimates increased with age, and was 
the largest in the age >75.0 years category (Figure 4.2), where we also saw the largest mean 
absolute bias (0.011, 0.025, and 0.025 at 5, 10, and 15 years of follow-up, respectively).  
Augmenting competing-risks cases (Method 2), and especially augmenting both the 
competing-risks cases and the controls (Method 1), reduced the bias in the estimates of the 
relative risks of dying from other causes and thus also the bias in the estimates of the absolute 
risks of dying from prostate cancer in the competing-risks setting (results presented in the 
supplementary material for Study I). 
Figure 4.1. Cause-specific log hazard ratios (HR) for the risks of dying from prostate cancer (A) and other 
causes (B) in the NPCR (black) and ProMort (plum) 
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4.2 Study II 
In Study II, we used 139,515 men diagnosed with prostate cancer, of whom 15,961 (11.4%) 
died from prostate cancer, to systematically compare how well the most commonly used 
pretreatment risk stratification tools predict death from prostate cancer. 
Overall, all tools discriminated death from prostate cancer well, and the C-index ranged from 
0.73 (95% CI: 0.72-0.73) to 0.80 (95% CI: 0.80-0.81) at 10 years. As expected, the 
discrimination generally improved with the increasing granularity of the risk stratification 
tool and was lowest for the three-tiered D’Amico risk group system and highest for the 
MSKCC nomograms (Figure 4.3).  
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Figure 4.2. Cumulative incidence function and 95% confidence intervals of dying from prostate cancer at 5 (A), 
10 (B) and 15 (C) years of follow-up in the NPCR (black) and ProMort I (plum) 
 
  35 
 
Figure 4.3. Pooled concordance index for prostate cancer death 
 
 
Figure 4.4. Range of the MSKCC nomogram predicted probabilities of dying from prostate cancer within the 
D’Amico risk groups. We used the average predicted cumulative incidences in the deciles of the MSKCC 
nomogram. Vertical red lines indicate the average predicted probability in each D’Amico risk group at 5 (A), 10 
(B) and 15 (C) years of follow-up 
 
 
The probabilities of dying from prostate cancer predicted using the D’Amico risk group 
system and the MSKCC nomogram are presented in Figure 4.4. The probability of dying 
from prostate cancer 15 years after diagnosis was 3.1%, 8.3% and 29.5% for men diagnosed 
with the low-, intermediate- and high-risk cancer according to the D’Amico criteria (Figure 
4.4C). The individual probabilities of dying from prostate cancer predicted using the MSKCC 
nomogram varied widely within each D’Amico risk group. The predicted probabilities ranged 
from 1.6-20.6%, 1.6-40.5% and 1.6-49.4% within the low-, intermediate- and high- D’Amico 
risk groups, respectively (Figure 4.4C).  
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When evaluated in different treatment groups, the discrimination was similar among men in 
the active surveillance/watchful waiting group and men in the radical prostatectomy/radiation 
therapy group. However, among men treated with primary androgen deprivation therapy, the 
discrimination was substantially poorer ranging from 0.56 (95% CI: 0.55-0.56) to 0.64 (95% 
CI: 0.63-0.65). For all risk stratification tools, the discrimination improved in more recently 
diagnosed cohorts. Among men diagnosed before 2003, the discrimination ranged from 0.66 
(95% CI: 0.65-0.67) to 0.73 (95% CI: 0.72-0.75) compared to 0.77 (95% CI: 0.76–0.78) to 
0.85 (95% CI: 0.84-0.86) among men diagnosed 2007-2016.  
For all risk stratification tools, the observed and predicted probabilities of dying from prostate 
cancer were generally similar. However, the predicted probabilities were generally 
underestimated, especially at 5 years of follow-up, in the highest-risk category of the NCCN 
system, CAPRA score, and deciles of the MSKCC linear predictor.  
4.3 Study III 
In Study III, we evaluated if light and virtual microscopy can be used interchangeably for the 
histopathological evaluation of prostate cancer by examining the repeatability (i.e., intra-
observer agreement) and reproducibility (i.e., inter-observer agreement) of the ISUP 
2014/WHO 2016 Gleason grading system using both microscopy methods. 
The intra-observer agreement for most of the features evaluated on the core level was similar 
for the two methods (Figure 4.5A), indicating good repeatability regardless of the method 
used. For the Gleason related features, the agreement ranged from substantial to almost 
perfect (primary Gleason pattern: κwLM=0.80 vs. κwVM=0.84; secondary Gleason pattern: 
κwLM=0.67 vs. κwVM=0.66; GGs: κwLM=0.85 vs. κwVM=0.84). For features which were rare, or 
for which reporting is not obligatory in clinical practice, such as intraductal cancer, the 
agreement was somewhat lower, but better when virtual microscopy was used (Figure 4.5A). 
The intra-observer agreement for the percentage of Gleason pattern 4 was overall poor, but, 
again, somewhat better on virtual microscopy. 
The inter-observer agreement for the Gleason-related features was similar for the two 
methods (Figure 4.5B), ranging from moderate/substantial to almost perfect (primary Gleason 
pattern: κwLM=0.72-0.90 vs. κwVM=0.78-0.80; secondary Gleason pattern: κwLM=0.58-0.75 vs. 
κwVM=0.67-0.68; GGs: κwLM=0.80-0.89 vs. κwVM=0.83) indicating good reproducibility 
regardless of the method used. For the remaining features, the agreement was somewhat 
lower, but similar for the two methods, except for mucinous carcinoma, perineural invasion, 
small-cell signet ring cell-like carcinoma, HGPIN and chronic inflammation, where it was 
better for light than virtual microscopy (Figure 4.5B). The inter-observer agreement for the 
percentage of Gleason pattern 4 was overall poor. 
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Finally, the median agreement between light and virtual microscopy was similar to the 
average/median agreement within the two methods, both when it was evaluated intra-
observer (Figure 4.5C) and inter-observer (Figure 4.5D), indicating interchangeability of light 
and virtual microscopy for most of the evaluated features. However, for most of the features 
Figure 4.5. Repeatability (A), reproducibility (B) and interchangeability (C, D) plot for all characteristics 
evaluated on the core and slide level  
Abbreviations: LM, Light microscopy; VM, Virtual microscopy; GGs, Gleason Grade Groups; GS, Gleason 
score; CN, Comedonecrosis; G1, Primary Gleason pattern; SCSR, Small-cell signet ring cell-like cancer; G2, 
Secondary Gleason pattern; CP, Cribriform pattern; MC, Mucinous cancer; PNI, Perineural invasion; PFG, 
Poorly formed glands; PAH, Postatrophic hyperplasia; AcI, acute inflammation. IgI, Intraglandular 
inflammation; PgI, Periglandular inflammation; ChrI, chronic inflammation; HGPIN, High-grade prostatic 
intraepithelial neoplasia; StrI, Stromal cancer; IDC, Intraductal cancer 
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evaluated on the slide level, median inter-method intra-observer agreement was lower than 
the average intra-method intra-observer agreement (Figure 4.5C), probably due to the higher 
intra-observer agreement on virtual microscopy. The absolute difference between the 
percentage of Gleason pattern 4 measured using light vs. virtual microscopy was up to 22 
percentage points larger for both the intra- and inter-observer comparisons. These results 
indicate overestimation of the percentage of Gleason pattern 4 when light microscopy is used. 
4.4 Study IV 
In Study IV, we first evaluated if the ISUP 2005 and 2014 Gleason grading revisions have 
improved prediction of death from prostate cancer. Then we investigated if any additional 
histopathological feature predicts death from prostate cancers independently from the GGs, as 
well as independently from GGs, age, PSA and cT at diagnosis. 
The GGs and ISUP 2014 Gleason score performed equally and better than the pre-2005 
Gleason score back-transformed using only cribriform pattern or both cribriform and poorly 
formed glands in discriminating death from prostate cancer in univariable (p=0.003 and 
p=0.005, respectively) and multivariable models (p=0.066 and p=0.097, respectively). There 
was, however, no difference in discrimination between the ISUP 2014 Gleason score and the 
pre-2005 Gleason score back-transformed using only poorly formed glands (p=0.296 and 
p=0.830 in univariable and multivariable models) (Table 4.1). These results indicate that the 
small improvement in discrimination of the ISUP 2014 Gleason score vs. pre-2005 Gleason 
score could be due to classifying all cribriform patterns, rather than poorly formed glands, as 
Gleason pattern 4. 
 
Table 4.1. Prognostic performance of univariable and multivariable models with different Gleason grading 
system revisions in predicting death from prostate cancer  
 Univariable analysis1 Multivariable analysis2 
 AUC 95% CIs AUC 95% CIs 
Pre-2005 Gleason score3 0.820 0.790 0.850 0.845 0.818 0.873 
Pre-2005 Gleason score4 0.832 0.803 0.861 0.853 0.826 0.880 
Pre-2005 Gleason score5,6 0.819 0.789 0.849 0.844 0.816 0.872 
ISUP 2014 Gleason score 0.840 0.811 0.868 0.854 0.828 0.881 
Gleason Grade Groups 0.839 0.811 0.868 0.854 0.827 0.881 
Abbreviations: AUC, Area under the receiver operating curve; ISUP, International Society of Urological 
Pathology 
1 Adjusted for the matching variables (year and county of diagnosis, and follow-up time) and primary treatment 
2 Adjusted for the matching variables, clinical tumor stage, age, PSA level and primary treatment 
3 Back-transformation using the cribriform pattern only 
4 Back-transformation using the poorly formed glands only 
5 Back-transformation using the cribriform pattern and/or poorly formed glands 
6 362 cases and 360 controls used in the analysis due to the complete separation 
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Almost all evaluated histopathological features were predictors of death from prostate cancer 
in the univariable analysis. However, only comedonecrosis, HGPIN and the number of cores 
with ≥50% cancer involvement predicted death from prostate cancer independently of the 
GGs (Figure 4.6). After additional adjustment for age, cT and PSA at diagnosis, 
comedonecrosis (OR: 6.8, 95% CIs: 1.4-33.4) and HGPIN (OR: 0.6, 95% CIs: 0.4-0.9) 
remained individual predictors (Figure 4.6), however with minimal impact on the 
discrimination (AUC: 0.86 vs 0.85 for both features). We also evaluated if there were any 
statistical interactions between the histopathological factors and the GGs. Adding an 
interaction term improved the model only for the number of cores (likelihood ratio test: 
p=0.002) and percentage of Gleason grade 4 (likelihood ratio test: p=0.033). The percentage 
of Gleason grade 4 was associated with death from prostate cancer only among men with 
GG3 (OR: 1.05, 95% CIs: 1.01-1.09). The impact of the added interaction term on 
discrimination was, however, minimal.  
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5 Discussion 
This thesis focuses on improving prognostication for men with localized prostate cancer. 
Although it does not include a comprehensive evaluation of all aspects of prognostic 
modelling in prostate cancer, it addresses several very important issues related to study 
design, model development and model updating. Rather than discussing the study results one 
by one as is done within each study manuscript, in the following text I will discuss our 
findings in the context of the aforementioned issues.  
5.1 Study design for prognostic modelling in localized prostate cancer 
Localized prostate cancer, and especially low- and intermediate-risk prostate cancer, has a 
prolonged natural history, and long-term cancer-specific mortality in these patients is quite 
low. In a relatively recent study by Klotz et al. (252), the cancer-specific survival for men on 
active surveillance was 98.1% and 94.3% at 10 and 15 years of follow-up, respectively. 
Similarly, in PCBaSe, the observed 15-year cancer-specific mortality for men with D’Amico 
low- and intermediate-risk cancer who were treated with mixed modalities was 5.1% and 
12.2%, respectively (253). Thus, even 15 years after diagnosis, only a small proportion will 
have died from prostate cancer, which makes prostate cancer death a rare outcome in men 
with low- and intermediate-risk disease. This also means that to study such a rare outcome, 
we need large cohorts of men followed-up for a very long time. Collecting additional 
information from such large cohorts (e.g., through a central histopathological re-review) 
makes cohort study design unfeasible. This issue is not an uncommon issue and is typically 
addressed by using well-known cost-effective cohort sub-sampling designs, such as case-
cohort or nested case-control designs (254, 255).  
5.1.1 The nested case-control study design  
ProMort I and ProMort II were sampled with the above-described reasoning in mind. 
ProMort I is an ambitious ongoing project which aims to identify novel tissue-based 
molecular prognostic markers for men with low- and intermediate-risk prostate cancer. 
ProMort II, on the other hand, aims at identifying novel histopathological markers for men 
with localized (i.e., low-, intermediate- or high-risk) prostate cancer. For both ProMort I and 
ProMort II, the nested case-control design is an appropriate study design for identifying novel 
prognostic markers as it gives unbiased relative risk estimates, which is also what we 
observed in Study I. However, to understand if a novel marker actually improves prediction, 
it should be evaluated in addition to established prognostic factors, i.e., the “gold standard” 
prognostic model (256). This brings us to two very important questions:  
1. Is the nested case-control study design appropriate for the development of models to 
predict death from prostate cancer? 
2. What is the “gold standard” prognostic model in prostate cancer? 
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5.1.1.1 Predicting death from prostate cancer  
For a prognostic model to be clinically useful, estimates of absolute risks are essential. It has 
been shown that the nested case-control design can be used to obtain unbiased estimates of 
absolute risks if appropriately analyzed (221, 222, 224-226, 230). Appropriate analysis here 
implies the use of weights which are based on the inverse of the probability of being selected 
into the study (221, 225, 226). The inverse probability weighting methods are, however, 
underutilized in epidemiological practice, mostly because the weights are difficult to obtain 
without access to the underlying cohort. When the underlying cohort is available, the 
calculation of weights can be implemented in R using the multileNCC package (257), or in 
Stata, using the code we published as a part of Study I (218). Once the weights are correctly 
estimated, these methods deliver virtually identical information compared to the analysis of 
the entire cohort with the advantage of reduced costs and reduced computational burden.  
5.1.1.2 Competing events 
In addition to the estimates of prostate cancer-specific survival, Klotz et al. reported that, in 
the same cohort of men on active surveillance described above, overall survival was 80% and 
62% at 10 and 15 years of follow-up, respectively (252). This means that 10 and 15 years 
after a prostate cancer diagnosis, most men will be alive, and of those who have died, most 
will have died from causes other than prostate cancer (258-260). In the setting where a man 
with prostate cancer is more likely to die from a competing event, using the nested case 
control-study design to predict death from prostate cancer becomes more complicated.  
Nested case-control studies are selected on the outcome. In ProMort I, the cases were all men 
who had died from prostate cancer and the controls were selected from the men who were 
still alive and at risk of dying from prostate cancer at the time the corresponding case died. It 
has been shown that the inverse probability weighting methods can still be used to make valid 
inferences for secondary, nonexclusive, outcomes (227, 228). However, to make inference on 
competing risks, these methods need to be extended further. To use nested case-control 
studies for competing risks analysis, we need to either modify the control sampling (233), 
treat the nested case-control study as a missing-data problem (240) or sample an additional 
set of competing risk cases (229) or both competing risk cases and controls (230). In Study I, 
we showed that simply using the inverse probability weighting method leads to biased 
estimates of the relative risks of dying from other causes, and that this translates into biased 
estimates of the absolute risks of dying from prostate cancer. However, adding competing 
risk cases to the analysis, or even better, adding both competing risk cases and controls, 
minimized these biases in Study I. This shows that nested-case control study design can 
indeed be used for the development of models predicting death from prostate cancer in the 
competing risk setting, but only with additional extensions to the design. 
It is important to note that when the nested case-control sampling has already been done and 
the underlying cohort is not available, we can no longer modify the control sampling (233) 
nor can we treat the case-control study as a missing-data problem (240). If the nested case-
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control study design is to be used for more than just identification of novel prognostic 
markers, the above-described issues should be considered at the study design phase. Rather 
than trying to fix the issues by augmenting competing risks controls and/or cases (229, 230), 
or by resampling controls for the event of interest by using a different sampling strategy 
(233), both of which carry additional cost, we should instead consider if alternative designs, 
such as the case-cohort design, are more feasible.  
5.1.1.3 Non-rare (common) events 
As mentioned before, both ProMort I and ProMort II are nested case-control studies. 
However, there is an important difference in their sampling. In ProMort II, where we sampled 
cases and controls among all men with non-metastatic prostate cancer, death from prostate 
cancer was not as rare as it was among the men with low- and intermediate-risk cancer who 
were sampled in ProMort I. In fact, in the 11 counties in the NPCR from which ProMort II 
cases and controls were sampled, 8,076 men (out of 62,603) had died from prostate cancer by 
the end of follow-up (Figure 3.1). In this population, prostate cancer death is a non-rare, or 
even a common, event. Sampling all cases, as is typically done in nested case-control studies, 
would thus be unfeasible. Instead, in ProMort II, we used a modified nested case-control 
sampling design to select a sub-sample of all cases (n=500) and their corresponding controls 
(n=500). Such a nonrepresentative sampling of cases was outlined in a paper by Langholz 
and Borgan in 1995 (261), but, to the best of my knowledge, there were no examples of its 
application. A recent doctoral thesis, however, described how the inverse probability 
weighting methods can be extended to modified nested case-control and case-cohort studies 
(262). By using modified inverse probability weights we could, in theory, obtain estimates of 
the individual absolute risks of dying from prostate cancer in ProMort II. Whether we could 
also account for the competing events using the above-described methods, remains, for now, 
unclear.  
5.2 Current prognostic models in prostate cancer 
Pretreatment prognostic models, or risk stratification tools, are critical not only for the 
appropriate treatment decision-making at the time of diagnosis, but also for benchmarking the 
utility of novel prognostic markers. The risk stratification tools used in all major prostate 
cancer guidelines (EAU (37, 50), NICE (33), GUROC (34), AUA (35), and NCCN (36)) are 
based on the three-tiered D’Amico risk group system (49). It is becoming increasingly clear 
that, even with the additional sub-stratification of the D’Amico low-, intermediate- and high-
risk groups, these tools are just too crude to be used as the “gold standard” (263). Indeed, in 
Study II, we showed that subdividing the NCCN low-risk group into very low and low, the 
NCCN/AUA intermediate-risk group into favorable and unfavorable, and, finally, the NCCN 
high-risk group into the high and very high has a minimal impact on discrimination. Which of 
the currently used risk stratification tools is then best at predicting death from prostate 
cancer? 
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5.2.1 The best-performing prognostic model 
Of all the compared risk stratification tools in Study II, the more complex, model-based tools 
such as the MSKCC nomogram (83), CAPRA score (60) and CPG risk groups (53), 
discriminated death from prostate cancer better than D’Amico and D’Amico-derived risk 
groups. That discrimination improves when more complex risk stratification tools are used is 
an expected consequence of finer risk stratification and use of continuous information. 
However, it is important to note that the C-index is not a function of the actual predicted 
probabilities (264). The probability of the correct ranking of risks in pairs of men with and 
without the outcome is not a relevant measure of clinical utility. While in Study II we used 
the C-index as a convenient measure to rank risk stratification tools according to how well 
they discriminate death from prostate cancer, it is not obvious if a higher C-index translates 
into improved prediction of individual probabilities of dying from prostate cancer. 
When deciding on the appropriate treatment, a clinician is primarily interested in the 
individual probability of death from prostate cancer. The best performing tool should thus 
predict this probability as accurately as possible. All risk stratification tools evaluated in 
Study II had similar observed and predicted probabilities of death from prostate cancer with 
some underestimation in the highest-risk categories for the MSKCC nomogram, CAPRA 
score and NCCN risk groups. However, the compared observed and predicted probabilities 
are population averages. For the risk stratification tools which do not finely stratify men with 
higher risk prostate cancer, the average predicted probabilities are influenced by the larger 
number of men with lower risk prostate cancer within the same group. To demonstrate how 
lumping together a large group of men with different risks of dying from prostate using the 
D’Amico risk groups may influence clinical decision-making, we plotted a distribution of the 
individual risks predicted using the best performing tool, the MSKCC nomogram, within 
each D’Amico risk group (Figure 4.4). Although perhaps not sufficiently emphasized in the 
published paper, this joint distribution plot is striking. At 15 years, within the D’Amico 
intermediate-risk group, 25% of the men had a MSKCC predicted probability of dying from 
prostate cancer between 1.6% and 6%. This range corresponds to the range of MSKCC 
predicted values within the D’Amico low-risk group. Furthermore, over 50% of the men had 
a MSKCC predicted probability higher than the D’Amico intermediate-risk group probability 
(8.3%), and of them, 25% had a predicted probability of 13.4-20.6%, and some extreme cases 
had a predicted probability of 49.4% (Figure 4.4). A similar wide range of MSKCC predicted 
probabilities was present also within the NCCN risk groups (data not shown), which, again, 
demonstrates that simply sub-stratifying low-, intermediate- and high-risk groups is not 
sufficient. This finer risk stratification could surely facilitate treatment decision for some of 
the men in the D’Amico intermediate risk group. Of note, we performed no formal 
quantification of the clinical usefulness/net benefit of the prediction models, such as decision 
curve analysis, in Study II. 
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5.2.2 The best-performing vs. the “gold-standard” prognostic models 
There is no formal definition of the “gold standard” prognostic model in prostate cancer. 
Intuitively, such a model should be parsimonious and contain relevant, readily available 
baseline features which are established and strong predictors of death from prostate cancer. 
Special attention should be given to the functional form of continuous variables and presence 
of interaction between predictors (265). Of note, this is a gross simplification of the 
prognostic model development process, and there is an extensive literature focusing on the 
technical and practical aspects of the optimal model development and validation process 
(266). As previously mentioned, prognostic models in prostate cancer typically include the 
Gleason score, PSA and cT. Although age at diagnosis is a predictor of death from prostate 
cancer, of all risk stratification tool we evaluated in Study II, age was included only in the 
CAPRA score. 
The best-performing tools we identified in Study II (MSKCC nomogram, CAPRA score, 
CPG risk groups) improve prediction of death from prostate cancer when compared to the 
D’Amico and D’Amico-derived risk grouping systems. However, these tools are still sub-
optimal. For the MSKCC nomogram, at the time Study II was conducted, age was not 
included in the model and primary and secondary Gleason pattern were dichotomized. Both 
the CAPRA score and the CPG risk grouping system categorize PSA. The CAPRA score also 
dichotomizes primary and secondary Gleason pattern as well as age at diagnosis, which is 
reduced to the categories <50 and ≥50 years of age. Given the plethora of available 
prognostic models in prostate cancer (68, 74, 75, 77), development of novel models based on 
the standard clinical variables is difficult to justify (263). However, using one, or several, 
standard methods to update (267, 268) the existing best performing models could get them 
closer to the “gold standard” ideal. Until then, consistent adoption of one or a few of the best 
performing tools in both clinical practice and research will allow for more personalized 
treatment decisions, facilitate the introduction of novel biomarkers and improve 
comparability across studies. 
Of note, the pretreatment MSKCC nomogram was updated in 2020 to include age, which is 
modelled as a continuous variable, and to replace the dichotomized Gleason patterns with the 
full range of the GGs (269). These changes seem to have had a minimal impact on the 
MSKCC internally validated C-index (0.79 in 2019 vs. 0.79 in 2020). We cannot, however, 
exclude the possibility that even minimal improvements in discrimination could translate into 
a more correct risk stratification and more appropriate management for some patients. Thus, 
it remains to be seen how this updated model performs in predicting individual probabilities 
of death from prostate cancer, in the competing risks setting.  
5.3 Improvement of the prognostic model performance 
In the preceding text I only briefly hinted at the technical and practical complexities of 
prognostic model development (266). The performance of prognostic models can be 
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improved through, for example, careful selection of predictors, choosing the correct 
functional form of continuous predictors, reduction of predictor misclassification, the 
inclusion of interactions between predictors as well as through model-updating methods (265, 
266). Discussing all of these methods is beyond the scope of this thesis. Here I will focus 
only on improvement through reduction of predictor misclassification and on one of the 
model-updating methods: the addition of new prognostic markers to an existing model. These 
issues were addressed in Study III and IV. 
5.3.1 Reliability and measurement heterogeneity  
Reliability of the predictor variables and measurement heterogeneity are important issues in 
prognostic model development (270). Reliability refers to the repeatability (i.e., intra-
observer agreement) and/or reproducibility (i.e., inter-observer agreement). Measurement 
heterogeneity refers to differences in the procedure and/or instruments used to measure the 
predictors. It has been shown that prognostic models including unreliable/misclassified 
predictors perform suboptimally on internal (271, 272) and, especially, external validation 
(273-275). In prostate cancer, all standard variables used for developing prognostic models 
are known to be unreliably measured and/or are subject to measurement heterogeneity. As 
described in the Introduction of this thesis, PSA levels are subject to large analytical and 
biological variation (84), cT is based on subjective digital rectal examination (86), and the 
Gleason score is notorious for its low inter-observer agreement, which has been only 
minimally improved by the ISUP 2005 and 2014 revisions (Table 1.3).  
While the misclassification of PSA and cT was not directly addressed in this thesis, in Study 
II, we imputed cT2 and cT3 sub-stage to reduce misclassification of men in risk groups and to 
improve comparability across the different risk stratification tools. In Study III we evaluated 
the reliability (i.e., intra-method agreement) and the measurement heterogeneity (i.e., inter-
method agreement) of the ISUP 2014 Gleason grading system, including the Gleason score 
and the GGs as well as many other histopathological features (Table 3.2). Furthermore, in 
Study IV we evaluated the potential improvement in prostate cancer prognostication due to 
the revisions of the Gleason grading system. 
5.3.1.1 The ISUP 2014 Gleason Grading system 
The main aim of Study III was to demonstrate interchangeability of light and virtual 
microscopy for the purpose of using virtual microscopy for the central re-review of ProMort I 
and II. To achieve this aim we evaluated the repeatability and reproducibility of different 
histopathological features on both light and virtual microscopy.  
Overall, we found better repeatability and reproducibility of the ISUP 2014 Gleason grading 
system compared to previous studies which evaluated the pre-2005 Gleason score (103-107, 
143), ISUP 2005 Gleason score (109-115, 122, 142), ISUP 2014 Gleason score (116, 117) 
and GGs (116, 117). The agreement between the pathologists in Study III was better than the 
agreement in the studies evaluating the pre-2005 and ISUP 2005 Gleason score regardless of 
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the experience of the pathologists (general or uropathologists). For the ISUP 2014 Gleason 
score and GGs our pathologist agreed better than the general pathologists in previous studies 
(116, 117). Only one previous study has evaluated the agreement between uropathologists for 
the GGs and their results were similar to ours (118). Of note, the sample size in Study III was 
relatively small (n=60) and we evaluated the agreement only between two uropathologists 
who have been working together for more than 7 years. Our findings on agreement, thus, 
might not reflect the agreement between unrelated uropathologists, and they quite likely do 
not reflect the agreement between general pathologists.  
The interpretation of these results is not straightforward. It is possible that the changes 
introduced by the ISUP 2014 revision have improved the inter-observer agreement for the 
Gleason score. Improved agreement would indicate an improved reliability of the Gleason 
score, or GGs, and potentially improved prediction of death from prostate cancer. Indeed, in 
Study IV, we found that the ISUP 2014 Gleason score discriminates death from prostate 
cancer better than the pre-2005 Gleason score. However, it is unclear if the improved 
discrimination is explained by increased reliability of the ISUP 2014 Gleason score or by 
better classification of tumor aggressiveness. Our results indicate that this improvement could 
be due to classifying all cribriform patterns, rather than poorly formed glands, as Gleason 
pattern 4. As cribriform pattern seems to have an unfavorable biologic behavior (see also 
section 1.3.4.2), interpreting all cribriform patterns as Gleason pattern 4 could lead to better 
classification of men with aggressive disease. 
Furthermore, given the similar agreement within and between light and virtual microscopy in 
Study III, we also confirmed the interchangeability of virtual and light microscopy for the 
ISUP 2014 Gleason grading system (109, 112, 113, 199). These results indicate no 
measurement heterogeneity when the histopathological review is performed on light vs. 
virtual microscopy.  
5.3.1.2 Other histopathological features 
Compared to previous studies, in Study III we found better repeatability and reproducibility 
for cribriform pattern (276, 277), poorly formed glands (276, 277) and comedonecrosis (278), 
but not for the percentage of Gleason pattern 4 (277). For some of the features which are rare, 
or are rarely reported (e.g., intraductal cancer, inflammation, HGPIN and PAH), we did not 
find good repeatability and/or reproducibility. Unreliable measurements for these features, 
and for the percentage of Gleason pattern 4, caution against using them in prognostic models 
until repeatability and reproducibility are improved. For all these features, however, our 
findings were similar on light and virtual microscopy, which indicates interchangeability and 
little to no measurement heterogeneity of light vs. virtual microscopy. 
5.3.2 Model extension with a novel prognostic marker  
Finally, in Study IV, we evaluated some of the previously proposed or established 
histopathological markers as well as other histopathological features as predictors of death 
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from prostate cancer. Critical evaluation of novel prognostic markers can be summarized into 
several phases, including: proof of concept, prospective validation, evaluation of incremental 
value, and assessment of clinical utility and cost effectiveness (279). In study IV, we were 
interested in validating existing and identifying novel histopathological markers. We also 
evaluated whether these markers could improve a “gold standard” prediction model.  
While almost all evaluated histopathological features in Study IV predicted death from 
prostate cancer in univariable analyses, only the number of cores with ≥50% cancer 
involvement, comedonecrosis and HGPIN remained predictive independently of GGs. When 
these markers were added to a “gold standard” prognostic model, only comedonecrosis and 
HGPIN remained independent predictors of death from prostate cancer, although with 
minimal impact on discrimination (C-index: 0.86 vs 0.85). Notably, we did not use the best-
performing prognostic model identified in Study II as the “gold standard” model. Instead we 
used a somewhat optimized version including the whole range of the GGs, continuous age, 
PSA modeled using restricted cubic splines and cT. This model is actually quite similar to the 
update of the MSKCC nomogram in 2020 (269). In addition, by adding primary treatment in 
all the models, we also accounted for the potential variability in the outcome due to primary 
treatment. Our study is the first to show that the presence of comedonecrosis is prognostic 
even after adjustment for the GGs and other standard clinicopathological factors. While 
interesting, this finding may have limited clinical application, as all men with 
comedonecrosis are assigned GG5 and are thus typically recommended treatment. Finally, 
the inverse association of HGPIN with death from prostate cancer is opposite to the only 
study describing HGPIN as a predictor of lethal prostate cancer (280), and this result should 
be interpreted with care until confirmed or disputed by additional research.  
Given that ProMort II was sampled using a modified nested case-control sampling scheme, 
we evaluated the improvement in prediction only in terms of discrimination. By applying the 
modified inverse probability weights in the analysis of ProMort II we could, as discussed 
above, try to estimate the individual probabilities of dying from prostate cancer. This could 
help us understand if the identified histopathological markers actually improve risk 
stratification compared to the “gold standard” model, regardless of the minimal impact on the 
discrimination. 
5.3.2.1 Case level vs. core level 
Prostate cancer diagnosis is based on needle biopsy findings, where several biopsy cores are 
sampled per patient. However, this core-level information is usually not accounted for in the 
prognostic models. Instead, only case-level summaries are used. For example, the highest 
Gleason score on a single core or the global Gleason score are typically used to assign a case-
level Gleason score. While there seems to be no difference between the highest and the global 
Gleason score or GGs in predicting BCR (281), the global GGs seem to have slightly higher 
agreement with the GGs on radical prostatectomy (282). However, neither of these summary 
case-level measurements truly takes into account the different GGs in all the sampled cores. 
The recommendation to record the percentage of Gleason pattern 4/5 was an attempt to 
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quantify the extent of high grade cancer in the biopsy core(s). There are several proposed 
ways of including this information in the prognostic models and the overall percentage of 
Gleason pattern 4 seems to outperform the highest percentage of Gleason pattern 4 (174, 
180). How the information on the Gleason score/GGs and the percentage of Gleason pattern 
4/5 is to be best combined is also not clear. Furthermore, there seems to be no consensus on 
the best way to quantify tumor extent. Many different, highly correlated measures have been 
proposed (see also the section 1.3.4.1), with no clear recommendations on the “best” 
measure. Finally, for binary histopathological features, case-level summaries typically refer 
to presence or absence in any of the sampled cores. For example, a man with perineural 
invasion in one core is treated the same as a man with perineural invasion in all of the cores. 
By using a single-summary case-level measure, we are losing a lot of potentially prognostic 
information. One of the next steps in improving prognostic models in prostate cancer should 
thus be finding optimal ways of using the core-level information for each man. 
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6 Conclusions 
Study I. The nested case-control study design can be used to obtain unbiased estimates 
of the relative risks of dying from prostate cancer. However, in the competing 
risks setting, nested case-control studies with augmented competing-risks 
cases and controls provide more valid absolute risk estimates. Thus, without 
additional extensions to the design, nested-case control studies are not suitable 
for the development of models predicting death from prostate cancer in the 
competing risks setting.  
Study II. The MSKCC nomogram, CAPRA score and CPG system discriminate death 
from prostate cancer better than the D’Amico and D’Amico-based risk 
grouping systems. Using these tools leads to finer individual risk prediction 
and using them in clinical practice could improve treatment decisions. 
Furthermore, these tools should be used to benchmark novel biomarkers and 
using them consistently in research could improve comparability across 
studies.  
Study III. Our findings indicate that light microscopy and our internally developed 
virtual microscopy system can be used interchangeably. We found good 
repeatability and reproducibility for key histopathological features, such as the 
ISUP 2014 Gleason score, GGs, perineural invasion, and cribriform pattern. 
The repeatability and/or reproducibility for some of the rare, or rarely 
reported, features, and for the percentage of Gleason pattern 4, was poor and 
should be improved before they are used in clinical practice. 
Study IV. The ISUP 2014 Gleason score discriminates death from prostate cancer better 
than the pre-2005 Gleason score. This improvement is likely due to classifying 
all cribriform patterns, rather than poorly formed glands, as Gleason pattern 4.  
Comedonecrosis and HGPIN predict death from prostate cancer independently 
of the GGs, age, PSA and cT at diagnosis, however, their impact on model 
discrimination is minimal. Future studies should confirm our results and 
evaluate if adding comedonecrosis and/or HGPIN to the “gold standard” 
model  improves risk stratification. 
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7 Future directions 
Several important issues regarding the development of prognostic models, such as sampling 
designs and handling of competing events, have been discussed in the Methods and 
Discussion sections and will not be further expanded here. In this section I will focus on 
several topics which have not been covered in this thesis, but should, nevertheless, be thought 
of when developing prognostic models. These topics deal with the improvement of current 
practices of prognostic model development for prostate cancer, and in general. 
7.1 Dynamic prediction models 
The prognostic models discussed in this thesis are built using baseline features and are 
sometimes referred to as static models. Static models do not account for temporal changes in 
the population or in the features used for model development and they could become outdated 
over time. Furthermore, the implementation of prognostic models into clinical practice will 
change clinical decision-making and, ultimately, the outcome of interest. Consequently, risk 
predictions obtained using these models may be inaccurate which, in turn, leads to 
inappropriate treatment decision-making. Prognostic models, therefore, tend to become 
“victims of their own success” (283, 284). Models which account for the changes occurring 
over time are called dynamic models. In the current literature, dynamic prognostic modelling 
refers to either continuous model updating or to incorporation of time-dependent covariates.   
The performance of static prognostic models tends to deteriorate over time. This phenomenon 
is also known as calibration drift (285, 286). Calibration drift is a consequence of differences 
between the population used for model development and the population to which the model is 
applied. These differences may refer to shifts in the outcome rate, patient case mix, or 
associations between predictors and outcomes (287, 288). In this setting, dynamic modelling 
refers to the application of discrete or continuous model updating methods (289, 290). 
Discrete model updating methods use new data over time and apply one, or several, standard 
model updating methods, such as simple intercept correction, adjustment of coefficients, or 
inclusion of novel predictors in the model (287, 289, 290). Continuous, or Bayesian, model 
updating methods combine the information obtained from the past data with the new data to 
obtain updated estimates (289, 290). Such updating methods seem to have little impact on 
discrimination of the model. However, they often lead to improved calibration (290). 
In time-to-event data, dynamic prediction modelling refers to the incorporation of time-
dependent covariate information into the prognostic model (283). The time-dependent 
covariate information refers to the longitudinal covariate data collected during treatment or 
follow-up which is often stored in electronic health records. The two most common 
approaches to dynamic prediction modelling are joint modelling and landmark analysis (283, 
291), but other methods have also been described (292). Joint models simultaneously 
estimate the model for the longitudinal process and the model for the time-to-event data, 
while the landmark analysis consists of a series of Cox proportional hazards models estimated 
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at predefined landmark times. Furthermore, several different methods have been proposed to 
extend dynamic prediction modelling to the competing risks setting, such as extension of the 
dynamic landmark models (293), combination of the pseudo-observations with the landmark 
analysis (294) and extension of the landmark models to the Fine and Gray model, i.e., the 
landmark subdistribution hazards model and supermodel (295). 
Although rarely applied in practice, probably due to a lack of access to the longitudinal data, 
no available guidelines or implementation difficulties, dynamic prognostic models seem to 
improve the accuracy of the predicted individual risks (296, 297) and they should be 
implemented in future prognostic models (291).  
7.1.1 Multiparametric magnetic resonance imaging guided biopsy 
A very timely example of a potential cause of calibration drift is the implementation of 
multiparametric magnetic resonance imaging (mpMRI) in clinical practice. mpMRI before 
biopsy as a triage test has been shown to reduce the number of unnecessary biopsies (298) 
and it seems to be a cost-effective strategy for diagnosing clinically significant prostate 
cancer in biopsy-naïve men (299). mpMRI-guided biopsy procedure outperforms systematic 
biopsy procedure in the detection of significant cancer in the repeat-biopsy setting, while in 
biopsy-naïve men, a combination of mpMRI-guided biopsy and systematic biopsy performs 
the best (300, 301). These findings have already led to changes in prostate cancer guidelines. 
For example, in the 2019 edition of the EAU guidelines for prostate cancer, mpMRI is 
recommended prior to biopsy in patients with suspected clinically significant prostate cancer, 
both targeted and systematic biopsy are recommended for biopsy-naïve men, and for men 
with a prior negative biopsy only targeted biopsy is recommended, albeit weakly (50). 
Although mpMRI has moderate inter-observer reproducibility and the optimal number of 
targeted cores per mpMRI ROI is still not determined (302), once these are optimized, it is 
likely that mpMRI-guided biopsy will completely replace systematic biopsies.  
It is expected that the implementation of mpMRI-guided biopsies in clinical practice will lead 
to calibration drift of prognostic models in prostate cancer. Whether the performance of these 
models can be improved by model updating methods, such as including mpMRI-related 
information, or by accounting for the potential differences in biopsy cores sampled using 
mpMRI-guided biopsy vs. systematic biopsy procedure, remains to be seen.  
7.2 The role of treatment in clinical prediction models 
To guide treatment decision-making in men diagnosed with prostate cancer, individual 
probabilities of dying from prostate cancer predicted using prognostic models should reflect 
the probability of dying from prostate cancer in the absence of treatment. Most prognostic 
models for prostate cancer have been developed using selected populations of radically 
treated men or using mixed populations of treated and untreated men. Treatment lowers the 
risk of dying from prostate cancer, yet treatment is usually ignored when prognostic models 
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are developed. Not accounting for treatment when developing a prognostic model leads to 
underestimation of the probability of the outcome in untreated men (303), and to a biased 
model performance when validated in differently treated populations (304). 
When developing a prognostic model, treatment can be modeled either as a time-invariant 
variable or as a time-dependent variable. Groenwold et al. compared several methods of 
accounting for time-invariant treatment when developing a prognostic model for a binary 
outcome (303). They found that ignoring an effective treatment leads to incorrect predicted 
probabilities of the outcome, that restricting analysis to untreated individuals is suitable only 
when treatment allocation is random, and that, when treatment allocation is not random, 
including treatment as a covariate in the model results in better predictive performance 
compared to other methods (303). Sperrin et al. extended this work to time-dependent 
treatment (305). They proposed a counterfactual framework for the development of 
prognostic models and they showed that using marginal structural models resulted in 
unbiased predicted probabilities of a binary outcome (305). In a recent study, Pajouheshnia et 
al. evaluated seven strategies of accounting for time-dependent treatment when developing a 
prognostic model for time-to-event outcomes (306). They compared models where the 
treatment was ignored to models developed by excluding treated patients, censoring treated 
patients at the time of treatment, using inverse probability of treatment weighting, modelling 
treatment as a binary covariate, modelling treatment as a time-varying covariate and, finally, 
using marginal structural models with time-varying inverse probability of treatment weights. 
They confirmed that ignoring the treatment when developing a prognostic model is 
theoretically inferior. However, when compared to other methods, ignoring the treatment and 
modelling time-dependent treatment as a binary covariate led to only a small overestimation 
of the predicted probabilities of the outcome and model performance varied minimally when 
different approaches were used (306).  
Van Geloven et al. proposed a somewhat different approach (307), which was inspired by the 
European Medicines Agency framework for dealing with additional treatments started after 
baseline, and other post-baseline but pre-outcome events, in clinical trials (308). In this 
approach, the choice of strategy for accounting for time-dependent treatment should be based 
on the question the researcher wants to address using the prediction model (307). An 
overview of the four proposed strategies is presented in Table 6.1. Depending on the strategy, 
risk predictions may be very different. Thus, the question of interest and choice of the 
strategy should ideally be predefined. For example, pretreatment risk stratification tools in 
prostate cancer are used to guide treatment decision-making for newly diagnosed men. Thus 
clinicians are interested in the risk of dying from prostate cancer in the absence of treatment. 
According to the proposed framework, prognostic models addressing this question should be 
developed using the hypothetical strategy. 
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Table 6.1. Overview of four strategies for dealing with treatment initiation after baseline in prognostic models 
Strategy Estimand Example Estimators Key assumptions 
Ignore 
treatment 
Risk of the event, 
regardless of 
treatment 
Risk of cardiovascular 
events where some patients 
will initiate statins 
according to routine-care 
prescriptions 
Survival model for T, 
do not censor at V 
Treatment 
assignment policy 
in application 
setting similar to 
development data 
Composite Risk of the event or 
treatment initiation 
Risk of a composite of 
cardiovascular death, 
myocardial infarction and 
treatment with PCI or 
CABG 
Survival model for 
min(T, V) 
Treatment 
assignment policy 
in application 
setting similar to 
development data 
While 
untreated 
Risk of the event 
occurring before 
treatment is started 
Risk of dying while on the 
waiting list for a liver 
transplant 
Competing risks 
methods 
Treatment 
assignment policy 
in application 
setting similar to 
development data 
Hypothetical Risk of the event if 
treatment was never 
started 
Risk of a natural pregnancy 
without IVF treatment 
Survival model for T, 
censor at V or include 
treatment as time-
dependent covariate in 
the model and set to 0 
when predicting 
Exchangeability, 
consistency and 
positivity 
Abbreviations: Estimand, the target quantity that we aim to estimate; T, time to event of interest; V, time to start 
of treatment; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; IVF, in vitro 
fertilization 
Reprinted from Nan van Geloven et al. Prediction meets causal inference: the role of treatment in clinical 
prediction models. Eur J Epidemiol. 2020;35:619–630, licensed under Creative Commons CC BY. © 2020, 
Springer Nature 
7.3 Clinical utility 
Although there is a plethora of risk stratification tools in prostate cancer, the vast majority of 
them is not used by clinicians. To be implemented into standard clinical practice, it should be 
clear how these tools are intended to be used to guide treatment decision. However, risk 
stratification tools, or prognostic models in general, do not recommend decisions to 
clinicians. Instead, clinicians are provided with predicted probabilities of the outcome of 
interest without being told what to do with that information (309). It is also often not clear if 
treatment decisions based on the prognostic model will improve patient outcome(s) compared 
to treatment decisions based on the current standard of care. The gold standard for evaluating 
clinical utility is a randomized clinical trial where prediction-based decision-making is 
compared to standard of care decision-making. The implementation of such a trial is, 
however, both practically and ethically challenging. Sachs at al. proposed to use 
observational data to optimize a prediction-based decision rule and to evaluate its clinical 
utility by emulating a randomized clinical trial (310). The proposed framework consists of 
three separate steps:  
1. Development of a prognostic model,  
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2. Development and optimization of a proposed decision rule based on the prognostic 
model, and  
3. Evaluation of the clinical utility of the proposed decision rule. 
A step-by-step example of the proposed framework was made available in the appendix to the 
paper (310). These studies could then be used to motivate better-informed confirmatory 
randomized clinical trials. 
7.4  Life expectancy 
Given the risk of overtreatment, evaluation of life expectancy can help balance the potential 
for life gained against the potential for harm caused by treatment and is currently 
recommended for prostate cancer clinical decision-making in several guidelines (35, 36, 50). 
However, there are no clear recommendations regarding the best method to predict life 
expectancy and clinicians seem to either not consider it when making treatment decision, or 
are poor judges of it, and are prone to both under- and over-estimation, regardless of their 
experience (311-313). Despite the fact that there are several available tools and online 
calculators predicting life expectancy (312), in practice, simple age-adjusted life tables seem 
to still be the most commonly recommended (50) and used by clinicians. Predicting life 
expectancy using age alone might be satisfactory only for men without any additional 
comorbidities. However, age and comorbidity are independent predictors of other-cause 
mortality in men with prostate cancer (314, 315) and they should be both considered when 
making treatment decision (316, 317). Adding additional predictors of other-cause mortality 
would lead to more individual life expectancy predictions, improved decision-making and 
potentially decreased overtreatment. Given that most of the current tools predicting death 
from other causes in prostate cancer patients seem to either be inappropriate for clinical use, 
or to provide questionable estimates (318), developing and validating a novel life expectancy 
calculator (using population-based samples of treated and untreated men (316)) in addition to 
a novel dynamic model predicting death from prostate cancer in the competing risks setting 
should be the next step toward informed treatment decision-making. 
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